{
    "abstract": "Sacubitril/valsartan (LCZ696) is the first angiotensin receptor neprilysin inhibitor approved to reduce cardiovascular mortality and hospitalization in patients with heart failure with reduced ejection fraction. As neprilysin (NEP) is one of several enzymes known to degrade amyloid-\u03b2 (A\u03b2), there is a theoretical risk of A\u03b2 accumulation following long-term NEP inhibition. The primary objective of this study was to evaluate the potential effects of sacubitril/valsartan on central nervous system clearance of A\u03b2 isoforms in cynomolgus monkeys using the sensitive Stable Isotope Labeling Kinetics (SILK\u2122)-A\u03b2 methodology. The in vitro selectivity of valsartan, sacubitril, and its active metabolite sacubitrilat was established; sacubitrilat did not inhibit other human A\u03b2-degrading metalloproteases. In a 2-week study, sacubitril/valsartan (50\u00a0mg/kg/day) or vehicle was orally administered to female cynomolgus monkeys in conjunction with SILK\u2122-A\u03b2. Despite low cerebrospinal fluid (CSF) and brain penetration, CSF exposure to sacubitril was sufficient to inhibit NEP and resulted in an increase in the elimination half-life of A\u03b21-42 (65.3%; p\u00a0=\u00a00.026), A\u03b21-40 (35.2%; p\u00a0=\u00a00.04) and A\u03b2total (29.8%; p\u00a0=\u00a00.04) acutely; this returned to normal as expected with repeated dosing for 15\u00a0days. CSF concentrations of newly generated A\u03b2 (AUC(0\u201324\u00a0h)) indicated elevations in the more aggregable form A\u03b21-42 on day 1 (20.4%; p\u00a0=\u00a00.039) and day 15 (34.7%; p\u00a0=\u00a00.0003) and in shorter forms A\u03b21-40 (23.4%; p\u00a0=\u00a00.009), A\u03b21-38 (64.1%; p\u00a0=\u00a00.0001) and A\u03b2total (50.45%; p\u00a0=\u00a00.00002) on day 15. However, there were no elevations in any A\u03b2 isoforms in the brains of these monkeys on day 16. In a second study cynomolgus monkeys were administered sacubitril/valsartan (300\u00a0mg/kg) or vehicle control for 39\u00a0weeks; no microscopic brain changes or A\u03b2 deposition, as assessed by immunohistochemical staining, were present. Further clinical studies are planned to address the relevance of these findings.",
    "author_highlights": [
        {
            "endOffset": 23935,
            "sentence": "Sacubitril/valsartan reduced A\u03b2 clearance on day 1, but not after 15 daily doses.",
            "startOffset": 23854
        },
        {
            "endOffset": 24018,
            "sentence": "Sacubitril/valsartan increased CSF A\u03b2 but did not result in increases in brain A\u03b2.",
            "startOffset": 23936
        },
        {
            "endOffset": 24101,
            "sentence": "No A\u03b2 brain pathology in 39 week monkey study with high dose sacubitril/valsartan.",
            "startOffset": 24019
        }
    ],
    "bib_entries": {
        "bb0005": {
            "authors": [
                {
                    "first": "Haruhiko",
                    "initial": "H.",
                    "last": "Akiyama"
                },
                {
                    "first": "Hiromi",
                    "initial": "H.",
                    "last": "Kondo"
                },
                {
                    "first": "Kenji",
                    "initial": "K.",
                    "last": "Ikeda"
                },
                {
                    "first": "Masanori",
                    "initial": "M.",
                    "last": "Kato"
                },
                {
                    "first": "Patrick L.",
                    "initial": "P.L.",
                    "last": "McGeer"
                }
            ],
            "doi": "10.1016/S0006-8993(01)02390-3",
            "firstpage": "277",
            "issn": "00068993",
            "lastpage": "281",
            "pmid": "11384622",
            "pub_year": 2001,
            "title": "Immunohistochemical localization of neprilysin in the human cerebral cortex: Inverse association with vulnerability to amyloid \u03b2-protein (A\u03b2) deposition",
            "volume": "902"
        },
        "bb0010": {
            "authors": [
                {
                    "first": "Randall J.",
                    "initial": "R.J.",
                    "last": "Bateman"
                },
                {
                    "first": "Eric R.",
                    "initial": "E.R.",
                    "last": "Siemers"
                },
                {
                    "first": "Kwasi G.",
                    "initial": "K.G.",
                    "last": "Mawuenyega"
                },
                {
                    "first": "Guolin",
                    "initial": "G.",
                    "last": "Wen"
                },
                {
                    "first": "Karen R.",
                    "initial": "K.R.",
                    "last": "Browning"
                },
                {
                    "first": "Wendy C.",
                    "initial": "W.C.",
                    "last": "Sigurdson"
                },
                {
                    "first": "Kevin E.",
                    "initial": "K.E.",
                    "last": "Yarasheski"
                },
                {
                    "first": "Stuart W.",
                    "initial": "S.W.",
                    "last": "Friedrich"
                },
                {
                    "first": "Ronald B.",
                    "initial": "R.B.",
                    "last": "DeMattos"
                },
                {
                    "first": "Patrick C.",
                    "initial": "P.C.",
                    "last": "May"
                },
                {
                    "first": "Steven M.",
                    "initial": "S.M.",
                    "last": "Paul"
                },
                {
                    "first": "David M.",
                    "initial": "D.M.",
                    "last": "Holtzman"
                }
            ],
            "doi": "10.1002/ana.21623",
            "firstpage": "48",
            "issn": "03645134",
            "lastpage": "54",
            "pmid": "19360898",
            "pub_year": 2009,
            "title": "A \u03b3-secretase inhibitor decreases amyloid-\u03b2 production in the central nervous system",
            "volume": "66"
        },
        "bb0015": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Bourne"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Barnes"
                },
                {
                    "first": "B. A.",
                    "initial": "B.A.",
                    "last": "Taylor"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Turner"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Kenny"
                }
            ],
            "doi": "10.1042/bj2590069",
            "firstpage": "69",
            "issn": "02646021",
            "lastpage": "80",
            "pmid": "2655579",
            "pub_year": 1989,
            "title": "Membrane peptidases in the pig choroid plexus and on other cell surfaces in contact with the cerebrospinal fluid",
            "volume": "259"
        },
        "bb0020": {
            "authors": [
                {
                    "first": "Julie A.",
                    "initial": "J.A.",
                    "last": "Carson"
                },
                {
                    "first": "Anthony J.",
                    "initial": "A.J.",
                    "last": "Turner"
                }
            ],
            "doi": "10.1046/j.1471-4159.2002.00855.x",
            "firstpage": "1",
            "issn": "00223042",
            "lastpage": "8",
            "pmid": "12067222",
            "pub_year": 2002,
            "title": "\u03b2-amyloid catabolism: Roles for neprilysin (NEP) and other metallopeptidases?",
            "volume": "81"
        },
        "bb0025": {
            "authors": [
                {
                    "first": "James K.",
                    "initial": "J.K.",
                    "last": "Chambers"
                },
                {
                    "first": "Hiroyuki",
                    "initial": "H.",
                    "last": "Kuribayashi"
                },
                {
                    "first": "Shu Ichi",
                    "initial": "S.I.",
                    "last": "Ikeda"
                },
                {
                    "first": "Yumi",
                    "initial": "Y.",
                    "last": "Une"
                }
            ],
            "doi": "10.3109/13506129.2010.483119",
            "firstpage": "75",
            "issn": "13506129",
            "lastpage": "82",
            "pmid": "20462366",
            "pub_year": 2010,
            "title": "Distribution of neprilysin and deposit patterns of A\u03b2 subtypes in the brains of aged squirrel monkeys (Saimiri sciureus)",
            "volume": "17"
        },
        "bb0030": {
            "authors": [
                {
                    "first": "Jacquelynn J.",
                    "initial": "J.J.",
                    "last": "Cook"
                },
                {
                    "first": "Kristin R.",
                    "initial": "K.R.",
                    "last": "Wildsmith"
                },
                {
                    "first": "David B.",
                    "initial": "D.B.",
                    "last": "Gilberto"
                },
                {
                    "first": "Marie A.",
                    "initial": "M.A.",
                    "last": "Holahan"
                },
                {
                    "first": "Gene G.",
                    "initial": "G.G.",
                    "last": "Kinney"
                },
                {
                    "first": "Parker D.",
                    "initial": "P.D.",
                    "last": "Mathers"
                },
                {
                    "first": "Maria S.",
                    "initial": "M.S.",
                    "last": "Michener"
                },
                {
                    "first": "Eric A.",
                    "initial": "E.A.",
                    "last": "Price"
                },
                {
                    "first": "Mark S.",
                    "initial": "M.S.",
                    "last": "Shearman"
                },
                {
                    "first": "Adam J.",
                    "initial": "A.J.",
                    "last": "Simon"
                },
                {
                    "first": "Jennifer X.",
                    "initial": "J.X.",
                    "last": "Wang"
                },
                {
                    "first": "Guoxin",
                    "initial": "G.",
                    "last": "Wu"
                },
                {
                    "first": "Kevin E.",
                    "initial": "K.E.",
                    "last": "Yarasheski"
                },
                {
                    "first": "Randall J.",
                    "initial": "R.J.",
                    "last": "Bateman"
                }
            ],
            "doi": "10.1523/JNEUROSCI.1381-10.2010",
            "firstpage": "6743",
            "issn": "02706474",
            "lastpage": "6750",
            "pmid": "20463236",
            "pub_year": 2010,
            "title": "Acute \u03b3-secretase inhibition of nonhuman primate CNS shifts Amyloid Precursor Protein (APP) metabolism from amyloid-\u03b2 production to alternative APP fragments without amyloid-\u03b2 rebound",
            "volume": "30"
        },
        "bb0035": {
            "authors": [
                {
                    "first": "Huda S.",
                    "initial": "H.S.",
                    "last": "Darusman"
                },
                {
                    "first": "Jacub",
                    "initial": "J.",
                    "last": "Pandelaki"
                },
                {
                    "first": "Rahmad",
                    "initial": "R.",
                    "last": "Mulyadi"
                },
                {
                    "first": "Dondin",
                    "initial": "D.",
                    "last": "Sajuthi"
                },
                {
                    "first": "Indah A.",
                    "initial": "I.A.",
                    "last": "Putri"
                },
                {
                    "first": "Otto H.",
                    "initial": "O.H.",
                    "last": "Kalliokoski"
                },
                {
                    "first": "Josep",
                    "initial": "J.",
                    "last": "Call"
                },
                {
                    "first": "Klas S.P.",
                    "initial": "K.S.P.",
                    "last": "Abelson"
                },
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Schapiro"
                },
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Gjedde"
                },
                {
                    "first": "Jann",
                    "initial": "J.",
                    "last": "Hau"
                }
            ],
            "firstpage": "173",
            "issn": "17917549",
            "lastpage": "184",
            "pmid": "24632970",
            "pub_year": 2014,
            "title": "Poor memory performance in aged cynomolgus monkeys with hippocampal atrophy, depletion of amyloid beta 1-42 and accumulation of tau proteins in cerebrospinal fluid.",
            "volume": "28"
        },
        "bb0040": {
            "authors": [
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Debiec"
                },
                {
                    "first": "Jeroen",
                    "initial": "J.",
                    "last": "Nauta"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Coulet"
                },
                {
                    "first": "Mirjam",
                    "initial": "M.",
                    "last": "Van Der Burg"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Guigonis"
                },
                {
                    "first": "Thierry",
                    "initial": "T.",
                    "last": "Schurmans"
                },
                {
                    "first": "Emile",
                    "initial": "E.",
                    "last": "De Heer"
                },
                {
                    "first": "Florent",
                    "initial": "F.",
                    "last": "Soubrier"
                },
                {
                    "first": "Francoise",
                    "initial": "F.",
                    "last": "Janssen"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Ronco"
                }
            ],
            "doi": "10.1016/S0140-6736(04)17142-0",
            "firstpage": "1252",
            "issn": "01406736",
            "lastpage": "1259",
            "pmid": "15464186",
            "pub_year": 2004,
            "title": "Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies",
            "volume": "364"
        },
        "bb0045": {
            "authors": [
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Doering"
                },
                {
                    "first": "Gabriele",
                    "initial": "G.",
                    "last": "Meder"
                },
                {
                    "first": "Manuela",
                    "initial": "M.",
                    "last": "Hinnenberger"
                },
                {
                    "first": "Julian",
                    "initial": "J.",
                    "last": "Woelcke"
                },
                {
                    "first": "Lorenz M.",
                    "initial": "L.M.",
                    "last": "Mayr"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Hassiepen"
                }
            ],
            "doi": "10.1177/1087057108327328",
            "firstpage": "1",
            "issn": "10870571",
            "lastpage": "9",
            "pmid": "19171917",
            "pub_year": 2009,
            "title": "A fluorescence lifetime-based assay for protease inhibitor profiling on human kallikrein 7",
            "volume": "14"
        },
        "bb0050": null,
        "bb0055": null,
        "bb0060": {
            "authors": [
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Gaudoux"
                },
                {
                    "first": "G.",
                    "initial": "G.",
                    "last": "Boileau"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Crine"
                }
            ],
            "doi": "10.1002/jnr.490340407",
            "firstpage": "426",
            "issn": "03604012",
            "lastpage": "433",
            "pmid": "8474144",
            "pub_year": 1993,
            "title": "Localization of neprilysin (EC 3.4.24.11) mRNA in rat brain by in situ hybridization",
            "volume": "34"
        },
        "bb0065": {
            "authors": [
                {
                    "first": "G. G.",
                    "initial": "G.G.",
                    "last": "Glenner"
                },
                {
                    "first": "C. W.",
                    "initial": "C.W.",
                    "last": "Wong"
                },
                {
                    "first": "V.",
                    "initial": "V.",
                    "last": "Quaranta"
                },
                {
                    "first": "E. D.",
                    "initial": "E.D.",
                    "last": "Eanes"
                }
            ],
            "firstpage": "357",
            "issn": "02521172",
            "lastpage": "369",
            "pmid": "6242724",
            "pub_year": 1984,
            "title": "The amyloid deposits in Alzheimer's disease: Their nature and pathogenesis",
            "volume": "2"
        },
        "bb0070": {
            "authors": [
                {
                    "first": "Ibrahim",
                    "initial": "I.",
                    "last": "Gonz\u00e1lez-Marrero"
                },
                {
                    "first": "Lydia",
                    "initial": "L.",
                    "last": "Gim\u00e9nez-Llort"
                },
                {
                    "first": "Conrad E.",
                    "initial": "C.E.",
                    "last": "Johanson"
                },
                {
                    "first": "Emilia Mar\u00eda",
                    "initial": "E.M.",
                    "last": "Carmona-Calero"
                },
                {
                    "first": "Leandro",
                    "initial": "L.",
                    "last": "Casta\u00f1eyra-Ruiz"
                },
                {
                    "first": "Jos\u00e9 Miguel",
                    "initial": "J.M.",
                    "last": "Brito-Armas"
                },
                {
                    "first": "Agust\u00edn",
                    "initial": "A.",
                    "last": "Casta\u00f1eyra-Perdomo"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Castro-Fuentes"
                }
            ],
            "doi": "10.3389/fncel.2015.00017",
            "issn": "16625102",
            "pub_year": 2015,
            "title": "Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of alzheimer\u2019s disease",
            "volume": "9"
        },
        "bb0075": {
            "authors": [
                {
                    "first": "Mauro",
                    "initial": "M.",
                    "last": "Gori"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Senni"
                }
            ],
            "doi": "10.1586/14779072.2016.1128827",
            "firstpage": "145",
            "issn": "14779072",
            "lastpage": "153",
            "pmid": "26642078",
            "pub_year": 2016,
            "title": "Sacubitril/valsartan (LCZ696) for the treatment of heart failure",
            "volume": "14"
        },
        "bb0080": {
            "authors": [
                {
                    "first": "Jessie",
                    "initial": "J.",
                    "last": "Gu"
                },
                {
                    "first": "Adele",
                    "initial": "A.",
                    "last": "Noe"
                },
                {
                    "first": "Priya",
                    "initial": "P.",
                    "last": "Chandra"
                },
                {
                    "first": "Suliman",
                    "initial": "S.",
                    "last": "Al-Fayoumi"
                },
                {
                    "first": "Monica",
                    "initial": "M.",
                    "last": "Ligueros-Saylan"
                },
                {
                    "first": "Ramesh",
                    "initial": "R.",
                    "last": "Sarangapani"
                },
                {
                    "first": "Suzanne",
                    "initial": "S.",
                    "last": "Maahs"
                },
                {
                    "first": "Gary",
                    "initial": "G.",
                    "last": "Ksander"
                },
                {
                    "first": "Dean F.",
                    "initial": "D.F.",
                    "last": "Rigel"
                },
                {
                    "first": "Arco Y.",
                    "initial": "A.Y.",
                    "last": "Jeng"
                },
                {
                    "first": "Tsu Han",
                    "initial": "T.H.",
                    "last": "Lin"
                },
                {
                    "first": "Weiyi",
                    "initial": "W.",
                    "last": "Zheng"
                },
                {
                    "first": "William P.",
                    "initial": "W.P.",
                    "last": "Dole"
                }
            ],
            "firstpage": "401",
            "issn": "15524604",
            "lastpage": "414",
            "pmid": "19934029",
            "pub_year": 2010,
            "title": "Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).",
            "volume": "50"
        },
        "bb0085": {
            "authors": [
                {
                    "first": "Christian",
                    "initial": "C.",
                    "last": "Haass"
                },
                {
                    "first": "Christoph",
                    "initial": "C.",
                    "last": "Kaether"
                },
                {
                    "first": "Gopal",
                    "initial": "G.",
                    "last": "Thinakaran"
                },
                {
                    "first": "Sangram",
                    "initial": "S.",
                    "last": "Sisodia"
                }
            ],
            "doi": "10.1101/cshperspect.a006270",
            "issn": "21571422",
            "pmid": "22553493",
            "pub_year": 2012,
            "title": "Trafficking and proteolytic processing of APP",
            "volume": "2"
        },
        "bb0090": {
            "authors": [
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Heuer"
                },
                {
                    "first": "Rebecca F.",
                    "initial": "R.F.",
                    "last": "Rosen"
                },
                {
                    "first": "Amarallys",
                    "initial": "A.",
                    "last": "Cintron"
                },
                {
                    "first": "Lary C.",
                    "initial": "L.C.",
                    "last": "Walker"
                }
            ],
            "doi": "10.2174/138161212799315885",
            "firstpage": "1159",
            "issn": "13816128",
            "lastpage": "1169",
            "pmid": "22288403",
            "pub_year": 2012,
            "title": "Nonhuman primate models of alzheimer-like cerebral proteopathy",
            "volume": "18"
        },
        "bb0095": {
            "authors": [
                {
                    "first": "Steven",
                    "initial": "S.",
                    "last": "Howell"
                },
                {
                    "first": "Josephine",
                    "initial": "J.",
                    "last": "Nalbantoglu"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Crine"
                }
            ],
            "doi": "10.1016/0196-9781(95)00021-B",
            "firstpage": "647",
            "issn": "01969781",
            "lastpage": "652",
            "pmid": "7479298",
            "pub_year": 1995,
            "title": "Neutral endopeptidase can hydrolyze \u03b2-amyloid(1-40) but shows no effect on \u03b2-amyloid precursor protein metabolism",
            "volume": "16"
        },
        "bb0100": {
            "authors": [
                {
                    "first": "Nobuhisa",
                    "initial": "N.",
                    "last": "Iwata"
                },
                {
                    "first": "Satoshi",
                    "initial": "S.",
                    "last": "Tsubuki"
                },
                {
                    "first": "Yoshie",
                    "initial": "Y.",
                    "last": "Takaki"
                },
                {
                    "first": "Kaori",
                    "initial": "K.",
                    "last": "Watanabe"
                },
                {
                    "first": "Misaki",
                    "initial": "M.",
                    "last": "Sekiguchi"
                },
                {
                    "first": "Emi",
                    "initial": "E.",
                    "last": "Hosoki"
                },
                {
                    "first": "Maho",
                    "initial": "M.",
                    "last": "Kawashima-Morishima"
                },
                {
                    "first": "Hahn Jun",
                    "initial": "H.J.",
                    "last": "Lee"
                },
                {
                    "first": "Emi",
                    "initial": "E.",
                    "last": "Hama"
                },
                {
                    "first": "Yoko",
                    "initial": "Y.",
                    "last": "Sekine-Aizawa"
                },
                {
                    "first": "Takaomi C.",
                    "initial": "T.C.",
                    "last": "Saido"
                }
            ],
            "doi": "10.1038/72237",
            "firstpage": "143",
            "issn": "10788956",
            "lastpage": "150",
            "pmid": "10655101",
            "pub_year": 2000,
            "title": "Identification of the major A\u03b21-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition",
            "volume": "6"
        },
        "bb0105": {
            "authors": [
                {
                    "first": "Takeshi",
                    "initial": "T.",
                    "last": "Iwatsubo"
                },
                {
                    "first": "Asano",
                    "initial": "A.",
                    "last": "Odaka"
                },
                {
                    "first": "Nobuhiro",
                    "initial": "N.",
                    "last": "Suzuki"
                },
                {
                    "first": "Hidehiro",
                    "initial": "H.",
                    "last": "Mizusawa"
                },
                {
                    "first": "Nobuyuki",
                    "initial": "N.",
                    "last": "Nukina"
                },
                {
                    "first": "Yasuo",
                    "initial": "Y.",
                    "last": "Ihara"
                }
            ],
            "doi": "10.1016/0896-6273(94)90458-8",
            "firstpage": "45",
            "issn": "08966273",
            "lastpage": "53",
            "pmid": "8043280",
            "pub_year": 1994,
            "title": "Visualization of A\u03b242(43) and A\u03b240 in senile plaques with end-specific A\u03b2 monoclonals: Evidence that an initially deposited species is A\u03b242(43)",
            "volume": "13"
        },
        "bb0110": {
            "authors": [
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Karran"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Mercken"
                },
                {
                    "first": "Bart De",
                    "initial": "B.D.",
                    "last": "Strooper"
                }
            ],
            "doi": "10.1038/nrd3505",
            "firstpage": "698",
            "issn": "14741776",
            "lastpage": "712",
            "pmid": "21852788",
            "pub_year": 2011,
            "title": "The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics",
            "volume": "10"
        },
        "bb0115": {
            "authors": [
                {
                    "first": "Jean Charles",
                    "initial": "J.C.",
                    "last": "Lambert"
                },
                {
                    "first": "Carla A.",
                    "initial": "C.A.",
                    "last": "Ibrahim-Verbaas"
                },
                {
                    "first": "Denise",
                    "initial": "D.",
                    "last": "Harold"
                },
                {
                    "first": "Adam C.",
                    "initial": "A.C.",
                    "last": "Naj"
                },
                {
                    "first": "Rebecca",
                    "initial": "R.",
                    "last": "Sims"
                },
                {
                    "first": "C\u00e9line",
                    "initial": "C.",
                    "last": "Bellenguez"
                },
                {
                    "first": "Gyungah",
                    "initial": "G.",
                    "last": "Jun"
                },
                {
                    "first": "Anita L.",
                    "initial": "A.L.",
                    "last": "DeStefano"
                },
                {
                    "first": "Joshua C.",
                    "initial": "J.C.",
                    "last": "Bis"
                },
                {
                    "first": "Gary W.",
                    "initial": "G.W.",
                    "last": "Beecham"
                },
                {
                    "first": "Benjamin",
                    "initial": "B.",
                    "last": "Grenier-Boley"
                },
                {
                    "first": "Giancarlo",
                    "initial": "G.",
                    "last": "Russo"
                },
                {
                    "first": "Tricia A.",
                    "initial": "T.A.",
                    "last": "Thornton-Wells"
                },
                {
                    "first": "Nicola",
                    "initial": "N.",
                    "last": "Jones"
                },
                {
                    "first": "Albert V.",
                    "initial": "A.V.",
                    "last": "Smith"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Chouraki"
                },
                {
                    "first": "Charlene",
                    "initial": "C.",
                    "last": "Thomas"
                },
                {
                    "first": "M. Arfan",
                    "initial": "M.A.",
                    "last": "Ikram"
                },
                {
                    "first": "Diana",
                    "initial": "D.",
                    "last": "Zelenika"
                },
                {
                    "first": "Badri N.",
                    "initial": "B.N.",
                    "last": "Vardarajan"
                },
                {
                    "first": "Yoichiro",
                    "initial": "Y.",
                    "last": "Kamatani"
                },
                {
                    "first": "Chiao Feng",
                    "initial": "C.F.",
                    "last": "Lin"
                },
                {
                    "first": "Amy",
                    "initial": "A.",
                    "last": "Gerrish"
                },
                {
                    "first": "Helena",
                    "initial": "H.",
                    "last": "Schmidt"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Kunkle"
                },
                {
                    "first": "Nathalie",
                    "initial": "N.",
                    "last": "Fi\u00e9vet"
                },
                {
                    "first": "Philippe",
                    "initial": "P.",
                    "last": "Amouyel"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Pasquier"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Deramecourt"
                },
                {
                    "first": "Renee F.A.G.",
                    "initial": "R.F.A.G.",
                    "last": "De Bruijn"
                },
                {
                    "first": "Najaf",
                    "initial": "N.",
                    "last": "Amin"
                },
                {
                    "first": "Albert",
                    "initial": "A.",
                    "last": "Hofman"
                },
                {
                    "first": "Cornelia M.",
                    "initial": "C.M.",
                    "last": "Van Duijn"
                },
                {
                    "first": "Melanie L.",
                    "initial": "M.L.",
                    "last": "Dunstan"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Hollingworth"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Owen"
                },
                {
                    "first": "Michael C.",
                    "initial": "M.C.",
                    "last": "O'Donovan"
                },
                {
                    "first": "Lesley",
                    "initial": "L.",
                    "last": "Jones"
                },
                {
                    "first": "Peter A.",
                    "initial": "P.A.",
                    "last": "Holmans"
                },
                {
                    "first": "Valentina",
                    "initial": "V.",
                    "last": "Moskvina"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Williams"
                },
                {
                    "first": "Clinton",
                    "initial": "C.",
                    "last": "Baldwin"
                },
                {
                    "first": "Lindsay A.",
                    "initial": "L.A.",
                    "last": "Farrer"
                },
                {
                    "first": "Seung Hoan",
                    "initial": "S.H.",
                    "last": "Choi"
                },
                {
                    "first": "Kathryn L.",
                    "initial": "K.L.",
                    "last": "Lunetta"
                },
                {
                    "first": "Annette L.",
                    "initial": "A.L.",
                    "last": "Fitzpatrick"
                },
                {
                    "first": "Tamara B.",
                    "initial": "T.B.",
                    "last": "Harris"
                },
                {
                    "first": "Bruce M.",
                    "initial": "B.M.",
                    "last": "Psaty"
                },
                {
                    "first": "John R.",
                    "initial": "J.R.",
                    "last": "Gilbert"
                },
                {
                    "first": "Kara L.",
                    "initial": "K.L.",
                    "last": "Hamilton-Nelson"
                },
                {
                    "first": "Eden R.",
                    "initial": "E.R.",
                    "last": "Martin"
                },
                {
                    "first": "Margaret A.",
                    "initial": "M.A.",
                    "last": "Pericak-Vance"
                },
                {
                    "first": "Jonathan L.",
                    "initial": "J.L.",
                    "last": "Haines"
                },
                {
                    "first": "Vilmundur",
                    "initial": "V.",
                    "last": "Gudnason"
                },
                {
                    "first": "Palmi V.",
                    "initial": "P.V.",
                    "last": "Jonsson"
                },
                {
                    "first": "Gudny",
                    "initial": "G.",
                    "last": "Eiriksdottir"
                },
                {
                    "first": "Marie Th\u00e9r\u00e8se",
                    "initial": "M.T.",
                    "last": "Bihoreau"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Lathrop"
                },
                {
                    "first": "Otto",
                    "initial": "O.",
                    "last": "Valladares"
                },
                {
                    "first": "Laura B.",
                    "initial": "L.B.",
                    "last": "Cantwell"
                },
                {
                    "first": "Li San",
                    "initial": "L.S.",
                    "last": "Wang"
                },
                {
                    "first": "Gerard D.",
                    "initial": "G.D.",
                    "last": "Schellenberg"
                },
                {
                    "first": "Agustin",
                    "initial": "A.",
                    "last": "Ruiz"
                },
                {
                    "first": "Merc\u00e8",
                    "initial": "M.",
                    "last": "Boada"
                },
                {
                    "first": "Christiane",
                    "initial": "C.",
                    "last": "Reitz"
                },
                {
                    "first": "Richard",
                    "initial": "R.",
                    "last": "Mayeux"
                },
                {
                    "first": "Alfredo",
                    "initial": "A.",
                    "last": "Ramirez"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Maier"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Hanon"
                },
                {
                    "first": "Walter A.",
                    "initial": "W.A.",
                    "last": "Kukull"
                },
                {
                    "first": "Joseph D.",
                    "initial": "J.D.",
                    "last": "Buxbaum"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Campion"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Wallon"
                },
                {
                    "first": "Didier",
                    "initial": "D.",
                    "last": "Hannequin"
                },
                {
                    "first": "Paul K.",
                    "initial": "P.K.",
                    "last": "Crane"
                },
                {
                    "first": "Eric B.",
                    "initial": "E.B.",
                    "last": "Larson"
                },
                {
                    "first": "Tim",
                    "initial": "T.",
                    "last": "Becker"
                },
                {
                    "first": "Carlos",
                    "initial": "C.",
                    "last": "Cruchaga"
                },
                {
                    "first": "Alison M.",
                    "initial": "A.M.",
                    "last": "Goate"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Craig"
                },
                {
                    "first": "Janet A.",
                    "initial": "J.A.",
                    "last": "Johnston"
                },
                {
                    "first": "Bernadette",
                    "initial": "B.",
                    "last": "Mc-Guinness"
                },
                {
                    "first": "Stephen",
                    "initial": "S.",
                    "last": "Todd"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Passmore"
                },
                {
                    "first": "Claudine",
                    "initial": "C.",
                    "last": "Berr"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "Ritchie"
                },
                {
                    "first": "Oscar L.",
                    "initial": "O.L.",
                    "last": "Lopez"
                },
                {
                    "first": "Philip L.",
                    "initial": "P.L.",
                    "last": "De Jager"
                },
                {
                    "first": "Denis",
                    "initial": "D.",
                    "last": "Evans"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Lovestone"
                },
                {
                    "first": "Petroula",
                    "initial": "P.",
                    "last": "Proitsi"
                },
                {
                    "first": "John F.",
                    "initial": "J.F.",
                    "last": "Powell"
                },
                {
                    "first": "Luc",
                    "initial": "L.",
                    "last": "Letenneur"
                },
                {
                    "first": "Pascale",
                    "initial": "P.",
                    "last": "Barberger-Gateau"
                },
                {
                    "first": "Carole",
                    "initial": "C.",
                    "last": "Dufouil"
                },
                {
                    "first": "Jean Fran\u00e7ois",
                    "initial": "J.F.",
                    "last": "Dartigues"
                },
                {
                    "first": "Francisco J.",
                    "initial": "F.J.",
                    "last": "Mor\u00f3n"
                },
                {
                    "first": "David C.",
                    "initial": "D.C.",
                    "last": "Rubinsztein"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "St. George-Hyslop"
                },
                {
                    "first": "Kristel",
                    "initial": "K.",
                    "last": "Sleegers"
                },
                {
                    "first": "Karolien",
                    "initial": "K.",
                    "last": "Bettens"
                },
                {
                    "first": "Christine",
                    "initial": "C.",
                    "last": "Van Broeckhoven"
                },
                {
                    "first": "Matthew J.",
                    "initial": "M.J.",
                    "last": "Huentelman"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Gill"
                },
                {
                    "first": "Kristelle",
                    "initial": "K.",
                    "last": "Brown"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Morgan"
                },
                {
                    "first": "M. Ilyas",
                    "initial": "M.I.",
                    "last": "Kamboh"
                },
                {
                    "first": "Lina",
                    "initial": "L.",
                    "last": "Keller"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Fratiglioni"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Green"
                },
                {
                    "first": "Amanda J.",
                    "initial": "A.J.",
                    "last": "Myers"
                },
                {
                    "first": "Seth",
                    "initial": "S.",
                    "last": "Love"
                },
                {
                    "first": "Ekaterina",
                    "initial": "E.",
                    "last": "Rogaeva"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Gallacher"
                },
                {
                    "first": "Anthony",
                    "initial": "A.",
                    "last": "Bayer"
                },
                {
                    "first": "Jordi",
                    "initial": "J.",
                    "last": "Clarimon"
                },
                {
                    "first": "Alberto",
                    "initial": "A.",
                    "last": "Lleo"
                },
                {
                    "first": "Debby W.",
                    "initial": "D.W.",
                    "last": "Tsuang"
                },
                {
                    "first": "Lei",
                    "initial": "L.",
                    "last": "Yu"
                },
                {
                    "first": "David A.",
                    "initial": "D.A.",
                    "last": "Bennett"
                },
                {
                    "first": "Magda",
                    "initial": "M.",
                    "last": "Tsolaki"
                },
                {
                    "first": "Paola",
                    "initial": "P.",
                    "last": "Boss\u00f9"
                },
                {
                    "first": "Gianfranco",
                    "initial": "G.",
                    "last": "Spalletta"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Collinge"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Mead"
                },
                {
                    "first": "Sandro",
                    "initial": "S.",
                    "last": "Sorbi"
                },
                {
                    "first": "Benedetta",
                    "initial": "B.",
                    "last": "Nacmias"
                },
                {
                    "first": "Florentino",
                    "initial": "F.",
                    "last": "Sanchez-Garcia"
                },
                {
                    "first": "Maria Candida",
                    "initial": "M.C.",
                    "last": "Deniz Naranjo"
                },
                {
                    "first": "Nick C.",
                    "initial": "N.C.",
                    "last": "Fox"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Hardy"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Bosco"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Clarke"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Brayne"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Galimberti"
                },
                {
                    "first": "Michelangelo",
                    "initial": "M.",
                    "last": "Mancuso"
                },
                {
                    "first": "Fiona",
                    "initial": "F.",
                    "last": "Matthews"
                },
                {
                    "first": "Susanne",
                    "initial": "S.",
                    "last": "Moebus"
                },
                {
                    "first": "Patrizia",
                    "initial": "P.",
                    "last": "Mecocci"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Del Zompo"
                },
                {
                    "first": "Harald",
                    "initial": "H.",
                    "last": "Hampel"
                },
                {
                    "first": "Alberto",
                    "initial": "A.",
                    "last": "Pilotto"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Bullido"
                },
                {
                    "first": "Francesco",
                    "initial": "F.",
                    "last": "Panza"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Caffarra"
                },
                {
                    "first": "Manuel",
                    "initial": "M.",
                    "last": "Mayhaus"
                },
                {
                    "first": "Sabrina",
                    "initial": "S.",
                    "last": "Pichler"
                },
                {
                    "first": "Wei",
                    "initial": "W.",
                    "last": "Gu"
                },
                {
                    "first": "Matthias",
                    "initial": "M.",
                    "last": "Riemenschneider"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Lannfelt"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Ingelsson"
                },
                {
                    "first": "Hakon",
                    "initial": "H.",
                    "last": "Hakonarson"
                },
                {
                    "first": "Minerva M.",
                    "initial": "M.M.",
                    "last": "Carrasquillo"
                },
                {
                    "first": "Fanggeng",
                    "initial": "F.",
                    "last": "Zou"
                },
                {
                    "first": "Steven G.",
                    "initial": "S.G.",
                    "last": "Younkin"
                },
                {
                    "first": "Duane",
                    "initial": "D.",
                    "last": "Beekly"
                },
                {
                    "first": "Victoria",
                    "initial": "V.",
                    "last": "Alvarez"
                },
                {
                    "first": "Eliecer",
                    "initial": "E.",
                    "last": "Coto"
                },
                {
                    "first": "Cristina",
                    "initial": "C.",
                    "last": "Razquin"
                },
                {
                    "first": "Pau",
                    "initial": "P.",
                    "last": "Pastor"
                },
                {
                    "first": "Ignacio",
                    "initial": "I.",
                    "last": "Mateo"
                },
                {
                    "first": "Onofre",
                    "initial": "O.",
                    "last": "Combarros"
                },
                {
                    "first": "Kelley M.",
                    "initial": "K.M.",
                    "last": "Faber"
                },
                {
                    "first": "Tatiana M.",
                    "initial": "T.M.",
                    "last": "Foroud"
                },
                {
                    "first": "Hilkka",
                    "initial": "H.",
                    "last": "Soininen"
                },
                {
                    "first": "Mikko",
                    "initial": "M.",
                    "last": "Hiltunen"
                },
                {
                    "first": "Deborah",
                    "initial": "D.",
                    "last": "Blacker"
                },
                {
                    "first": "Thomas H.",
                    "initial": "T.H.",
                    "last": "Mosley"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Graff"
                },
                {
                    "first": "Clive",
                    "initial": "C.",
                    "last": "Holmes"
                },
                {
                    "first": "Thomas J.",
                    "initial": "T.J.",
                    "last": "Montine"
                },
                {
                    "first": "Jerome I.",
                    "initial": "J.I.",
                    "last": "Rotter"
                },
                {
                    "first": "Alexis",
                    "initial": "A.",
                    "last": "Brice"
                },
                {
                    "first": "Michael A.",
                    "initial": "M.A.",
                    "last": "Nalls"
                },
                {
                    "first": "John S.K.",
                    "initial": "J.S.K.",
                    "last": "Kauwe"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Boerwinkle"
                },
                {
                    "first": "Reinhold",
                    "initial": "R.",
                    "last": "Schmidt"
                },
                {
                    "first": "Dan",
                    "initial": "D.",
                    "last": "Rujescu"
                },
                {
                    "first": "Christophe",
                    "initial": "C.",
                    "last": "Tzourio"
                },
                {
                    "first": "Markus M.",
                    "initial": "M.M.",
                    "last": "N\u00f6then"
                },
                {
                    "first": "Lenore J.",
                    "initial": "L.J.",
                    "last": "Launer"
                },
                {
                    "first": "Sudha",
                    "initial": "S.",
                    "last": "Seshadri"
                }
            ],
            "doi": "10.1038/ng.2802",
            "firstpage": "1452",
            "issn": "10614036",
            "lastpage": "1458",
            "pub_year": 2013,
            "title": "Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease",
            "volume": "45"
        },
        "bb0120": {
            "authors": [
                {
                    "first": "Thomas H.",
                    "initial": "T.H.",
                    "last": "Langenickel"
                },
                {
                    "first": "Chiaki",
                    "initial": "C.",
                    "last": "Tsubouchi"
                },
                {
                    "first": "Surya",
                    "initial": "S.",
                    "last": "Ayalasomayajula"
                },
                {
                    "first": "Parasar",
                    "initial": "P.",
                    "last": "Pal"
                },
                {
                    "first": "Marie Anne",
                    "initial": "M.A.",
                    "last": "Valentin"
                },
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Hinder"
                },
                {
                    "first": "Stanford",
                    "initial": "S.",
                    "last": "Jhee"
                },
                {
                    "first": "Hakop",
                    "initial": "H.",
                    "last": "Gevorkyan"
                },
                {
                    "first": "Iris",
                    "initial": "I.",
                    "last": "Rajman"
                }
            ],
            "doi": "10.1111/bcp.12861",
            "firstpage": "878",
            "issn": "03065251",
            "lastpage": "890",
            "pmid": "26663387",
            "pub_year": 2016,
            "title": "The effect of LCZ696 (sacubitril/valsartan) on amyloid-\u03b2 concentrations in cerebrospinal fluid in healthy subjects",
            "volume": "81"
        },
        "bb0125": {
            "authors": [
                {
                    "first": "Malcolm A.",
                    "initial": "M.A.",
                    "last": "Leissring"
                }
            ],
            "doi": "10.1074/jbc.R800022200",
            "firstpage": "29645",
            "issn": "00219258",
            "lastpage": "29649",
            "pmid": "18723506",
            "pub_year": 2008,
            "title": "The A\u03b2Cs of A\u03b2-cleaving proteases",
            "volume": "283"
        },
        "bb0130": {
            "authors": [
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Mangiafico"
                },
                {
                    "first": "Lisa C.",
                    "initial": "L.C.",
                    "last": "Costello-Boerrigter"
                },
                {
                    "first": "Ingrid A.",
                    "initial": "I.A.",
                    "last": "Andersen"
                },
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Cataliotti"
                },
                {
                    "first": "John C.",
                    "initial": "J.C.",
                    "last": "Burnett"
                }
            ],
            "doi": "10.1093/eurheartj/ehs262",
            "firstpage": "886",
            "issn": "0195668X",
            "lastpage": "893",
            "pmid": "22942338",
            "pub_year": 2013,
            "title": "Neutral endopeptidase inhibition and the natriuretic peptide system: An evolving strategy in cardiovascular therapeutics",
            "volume": "34"
        },
        "bb0135": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Matsas"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Rattray"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Kenny"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Turner"
                }
            ],
            "doi": "10.1042/bj2280487",
            "firstpage": "487",
            "issn": "02646021",
            "lastpage": "492",
            "pmid": "2409961",
            "pub_year": 1985,
            "title": "The metabolism of neuropeptides. Endopeptidase-24.11 in human synaptic membrane preparations hydrolyses substance P",
            "volume": "228"
        },
        "bb0140": {
            "authors": [
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Matsas"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Kenny"
                },
                {
                    "first": "A. J.",
                    "initial": "A.J.",
                    "last": "Turner"
                }
            ],
            "doi": "10.1016/0306-4522(86)90113-2",
            "firstpage": "991",
            "issn": "03064522",
            "lastpage": "1012",
            "pmid": "3093917",
            "pub_year": 1986,
            "title": "An immunohistochemical study of endopeptidase-24.11 (\"enkephalinase\") in the pig nervous system",
            "volume": "18"
        },
        "bb0145": {
            "authors": [
                {
                    "first": "John J.V.",
                    "initial": "J.J.V.",
                    "last": "McMurray"
                }
            ],
            "doi": "10.1002/ejhf.250",
            "firstpage": "242",
            "issn": "13889842",
            "lastpage": "247",
            "pmid": "25756942",
            "pub_year": 2015,
            "title": "Neprilysin inhibition to treat heart failure: A tale of science, serendipity, and second chances",
            "volume": "17"
        },
        "bb0150": {
            "authors": [
                {
                    "first": "John J.V.",
                    "initial": "J.J.V.",
                    "last": "McMurray"
                },
                {
                    "first": "Milton",
                    "initial": "M.",
                    "last": "Packer"
                },
                {
                    "first": "Akshay S.",
                    "initial": "A.S.",
                    "last": "Desai"
                },
                {
                    "first": "Jianjian",
                    "initial": "J.",
                    "last": "Gong"
                },
                {
                    "first": "Martin P.",
                    "initial": "M.P.",
                    "last": "Lefkowitz"
                },
                {
                    "first": "Adel R.",
                    "initial": "A.R.",
                    "last": "Rizkala"
                },
                {
                    "first": "Jean L.",
                    "initial": "J.L.",
                    "last": "Rouleau"
                },
                {
                    "first": "Victor C.",
                    "initial": "V.C.",
                    "last": "Shi"
                },
                {
                    "first": "Scott D.",
                    "initial": "S.D.",
                    "last": "Solomon"
                },
                {
                    "first": "Karl",
                    "initial": "K.",
                    "last": "Swedberg"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Zile"
                }
            ],
            "doi": "10.1056/NEJMoa1409077",
            "firstpage": "993",
            "issn": "00284793",
            "lastpage": "1004",
            "pmid": "25176015",
            "pub_year": 2014,
            "title": "Angiotensin-neprilysin inhibition versus enalapril in heart failure",
            "volume": "371"
        },
        "bb0155": {
            "authors": [
                {
                    "first": "Natalia N.",
                    "initial": "N.N.",
                    "last": "Nalivaeva"
                },
                {
                    "first": "Nikolai D.",
                    "initial": "N.D.",
                    "last": "Belyaev"
                },
                {
                    "first": "Caroline",
                    "initial": "C.",
                    "last": "Kerridge"
                },
                {
                    "first": "Anthony J.",
                    "initial": "A.J.",
                    "last": "Turner"
                }
            ],
            "doi": "10.3389/fnagi.2014.00235",
            "firstpage": "1",
            "issn": "16634365",
            "lastpage": "33",
            "pub_year": 2014,
            "title": "Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease",
            "volume": "6"
        },
        "bb0160": {
            "authors": [
                {
                    "first": "Ingrid D.",
                    "initial": "I.D.",
                    "last": "Pardo"
                },
                {
                    "first": "Robert H.",
                    "initial": "R.H.",
                    "last": "Garman"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Weber"
                },
                {
                    "first": "Walter F.",
                    "initial": "W.F.",
                    "last": "Bobrowski"
                },
                {
                    "first": "Jerry F.",
                    "initial": "J.F.",
                    "last": "Hardisty"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Morton"
                }
            ],
            "doi": "10.1177/0192623311436180",
            "firstpage": "624",
            "issn": "01926233",
            "lastpage": "636",
            "pmid": "22317925",
            "pub_year": 2012,
            "title": "Technical guide for nervous system sampling of the cynomolgus monkey for general toxicity studies",
            "volume": "40"
        },
        "bb0165": {
            "authors": [
                {
                    "first": "Marcia B.",
                    "initial": "M.B.",
                    "last": "Podlisny"
                },
                {
                    "first": "Dean R.",
                    "initial": "D.R.",
                    "last": "Tolan"
                },
                {
                    "first": "Dennis J.",
                    "initial": "D.J.",
                    "last": "Selkoe"
                }
            ],
            "firstpage": "1423",
            "issn": "00029440",
            "lastpage": "1435",
            "pmid": "1905108",
            "pub_year": 1991,
            "title": "Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease",
            "volume": "138"
        },
        "bb0170": {
            "authors": [
                {
                    "first": "H\u00e9l\u00e8ne",
                    "initial": "H.",
                    "last": "Pollard"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Llorens-Cortes"
                },
                {
                    "first": "Jean Yves",
                    "initial": "J.Y.",
                    "last": "Couraud"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Ronco"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Verroust"
                },
                {
                    "first": "Jean Charles",
                    "initial": "J.C.",
                    "last": "Schwartz"
                }
            ],
            "doi": "10.1016/0304-3940(87)90510-6",
            "firstpage": "267",
            "issn": "03043940",
            "lastpage": "271",
            "pmid": "2441326",
            "pub_year": 1987,
            "title": "Enkephalinase (EC 3.4.24.11) is highly localized to a striatonigral pathway in rat brain",
            "volume": "77"
        },
        "bb0175": {
            "authors": [
                {
                    "first": "Kaleigh Filisa",
                    "initial": "K.F.",
                    "last": "Roberts"
                },
                {
                    "first": "Donald L.",
                    "initial": "D.L.",
                    "last": "Elbert"
                },
                {
                    "first": "Tom P.",
                    "initial": "T.P.",
                    "last": "Kasten"
                },
                {
                    "first": "Bruce W.",
                    "initial": "B.W.",
                    "last": "Patterson"
                },
                {
                    "first": "Wendy C.",
                    "initial": "W.C.",
                    "last": "Sigurdson"
                },
                {
                    "first": "Rose E.",
                    "initial": "R.E.",
                    "last": "Connors"
                },
                {
                    "first": "Vitaliy",
                    "initial": "V.",
                    "last": "Ovod"
                },
                {
                    "first": "Ling Y.",
                    "initial": "L.Y.",
                    "last": "Munsell"
                },
                {
                    "first": "Kwasi G.",
                    "initial": "K.G.",
                    "last": "Mawuenyega"
                },
                {
                    "first": "Michelle M.",
                    "initial": "M.M.",
                    "last": "Miller-Thomas"
                },
                {
                    "first": "Christopher J.",
                    "initial": "C.J.",
                    "last": "Moran"
                },
                {
                    "first": "Dewitte T.",
                    "initial": "D.T.",
                    "last": "Cross"
                },
                {
                    "first": "Colin P.",
                    "initial": "C.P.",
                    "last": "Derdeyn"
                },
                {
                    "first": "Rall J.",
                    "initial": "R.J.",
                    "last": "Bateman"
                }
            ],
            "doi": "10.1002/ana.24270",
            "firstpage": "837",
            "issn": "03645134",
            "lastpage": "844",
            "pmid": "25205593",
            "pub_year": 2014,
            "title": "Amyloid-\u03b2 efflux from the central nervous system into the plasma",
            "volume": "76"
        },
        "bb0180": {
            "authors": [
                {
                    "first": "Takaomi",
                    "initial": "T.",
                    "last": "Saido"
                },
                {
                    "first": "Malcolm A.",
                    "initial": "M.A.",
                    "last": "Leissring"
                }
            ],
            "doi": "10.1101/cshperspect.a006379",
            "issn": "21571422",
            "pmid": "22675659",
            "pub_year": 2012,
            "title": "Proteolytic degradation of amyloid \u03b2-protein",
            "volume": "2"
        },
        "bb0185": {
            "authors": [
                {
                    "first": "Yoshie",
                    "initial": "Y.",
                    "last": "Takaki"
                },
                {
                    "first": "Nobuhisa",
                    "initial": "N.",
                    "last": "Iwata"
                },
                {
                    "first": "Satoshi",
                    "initial": "S.",
                    "last": "Tsubuki"
                },
                {
                    "first": "Sayuri",
                    "initial": "S.",
                    "last": "Taniguchi"
                },
                {
                    "first": "Satoshi",
                    "initial": "S.",
                    "last": "Toyoshima"
                },
                {
                    "first": "Bao",
                    "initial": "B.",
                    "last": "Lu"
                },
                {
                    "first": "Norma P.",
                    "initial": "N.P.",
                    "last": "Gerard"
                },
                {
                    "first": "Craig",
                    "initial": "C.",
                    "last": "Gerard"
                },
                {
                    "first": "Hahn Jun",
                    "initial": "H.J.",
                    "last": "Lee"
                },
                {
                    "first": "Keiro",
                    "initial": "K.",
                    "last": "Shirotani"
                },
                {
                    "first": "Takaomi C.",
                    "initial": "T.C.",
                    "last": "Saido"
                }
            ],
            "doi": "10.1093/oxfordjournals.jbchem.a022839",
            "firstpage": "897",
            "issn": "0021924X",
            "lastpage": "902",
            "pmid": "11098130",
            "pub_year": 2000,
            "title": "Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid \u03b2 peptide in the brain",
            "volume": "128"
        },
        "bb0190": {
            "authors": [
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Takeuchi"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Uetsuka"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Murayama"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Kikuta"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Takashima"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Doi"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Nakayama"
                }
            ],
            "doi": "10.1354/vp.45-4-455",
            "firstpage": "455",
            "issn": "03009858",
            "lastpage": "466",
            "pmid": "18587091",
            "pub_year": 2008,
            "title": "Complementary distributions of amyloid-\u03b2 and neprilysin in the brains of dogs and cats",
            "volume": "45"
        },
        "bb0195": {
            "authors": [
                {
                    "first": "Jenna M.",
                    "initial": "J.M.",
                    "last": "Tarasoff-Conway"
                },
                {
                    "first": "Roxana O.",
                    "initial": "R.O.",
                    "last": "Carare"
                },
                {
                    "first": "Ricardo S.",
                    "initial": "R.S.",
                    "last": "Osorio"
                },
                {
                    "first": "Lidia",
                    "initial": "L.",
                    "last": "Glodzik"
                },
                {
                    "first": "Tracy",
                    "initial": "T.",
                    "last": "Butler"
                },
                {
                    "first": "Els",
                    "initial": "E.",
                    "last": "Fieremans"
                },
                {
                    "first": "Leon",
                    "initial": "L.",
                    "last": "Axel"
                },
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Rusinek"
                },
                {
                    "first": "Charles",
                    "initial": "C.",
                    "last": "Nicholson"
                },
                {
                    "first": "Berislav V.",
                    "initial": "B.V.",
                    "last": "Zlokovic"
                },
                {
                    "first": "Blas",
                    "initial": "B.",
                    "last": "Frangione"
                },
                {
                    "first": "Kaj",
                    "initial": "K.",
                    "last": "Blennow"
                },
                {
                    "first": "Jo\u00ebl",
                    "initial": "J.",
                    "last": "M\u00e9nard"
                },
                {
                    "first": "Henrik",
                    "initial": "H.",
                    "last": "Zetterberg"
                },
                {
                    "first": "Thomas",
                    "initial": "T.",
                    "last": "Wisniewski"
                },
                {
                    "first": "Mony J.",
                    "initial": "M.J.",
                    "last": "De Leon"
                }
            ],
            "doi": "10.1038/nrneurol.2015.119",
            "firstpage": "457",
            "issn": "17594758",
            "lastpage": "470",
            "pmid": "26195256",
            "pub_year": 2015,
            "title": "Clearance systems in the brain - Implications for Alzheimer disease",
            "volume": "11"
        },
        "bb0200": {
            "authors": [
                {
                    "first": "Massimo",
                    "initial": "M.",
                    "last": "Volpe"
                },
                {
                    "first": "Marino",
                    "initial": "M.",
                    "last": "Carnovali"
                },
                {
                    "first": "Vittoria",
                    "initial": "V.",
                    "last": "Mastromarino"
                }
            ],
            "doi": "10.1042/CS20150469",
            "firstpage": "57",
            "issn": "01435221",
            "lastpage": "77",
            "pmid": "26637405",
            "pub_year": 2016,
            "title": "The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment",
            "volume": "130"
        },
        "bb0205": {
            "authors": [
                {
                    "first": "Yan Jiang",
                    "initial": "Y.J.",
                    "last": "Wang"
                },
                {
                    "first": "Hua Dong",
                    "initial": "H.D.",
                    "last": "Zhou"
                },
                {
                    "first": "Xin Fu",
                    "initial": "X.F.",
                    "last": "Zhou"
                }
            ],
            "doi": "10.1016/j.drudis.2006.08.004",
            "firstpage": "931",
            "issn": "13596446",
            "lastpage": "938",
            "pmid": "16997144",
            "pub_year": 2006,
            "title": "Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives",
            "volume": "11"
        },
        "bb7000": {
            "authors": [
                {
                    "first": "Pierpaolo",
                    "initial": "P.",
                    "last": "Sorrentino"
                },
                {
                    "first": "Antonietta",
                    "initial": "A.",
                    "last": "Iuliano"
                },
                {
                    "first": "Arianna",
                    "initial": "A.",
                    "last": "Polverino"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Jacini"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Sorrentino"
                }
            ],
            "doi": "10.1016/j.febslet.2013.12.038",
            "firstpage": "641",
            "issn": "00145793",
            "lastpage": "652",
            "pmid": "24491999",
            "pub_year": 2014,
            "title": "The dark sides of amyloid in Alzheimer's disease pathogenesis",
            "volume": "588"
        },
        "bb9005": {
            "authors": [
                {
                    "first": "Takeshi",
                    "initial": "T.",
                    "last": "Iwatsubo"
                },
                {
                    "first": "David M.A.",
                    "initial": "D.M.A.",
                    "last": "Mann"
                },
                {
                    "first": "Asano",
                    "initial": "A.",
                    "last": "Odaka"
                },
                {
                    "first": "Nobuhiro",
                    "initial": "N.",
                    "last": "Suzuki"
                },
                {
                    "first": "Yasuo",
                    "initial": "Y.",
                    "last": "Ihara"
                }
            ],
            "doi": "10.1002/ana.410370305",
            "firstpage": "294",
            "issn": "03645134",
            "lastpage": "299",
            "pmid": "7695229",
            "pub_year": 1995,
            "title": "Amyloid \u03b2 protein (A\u03b2) deposition: A\u03b242(43) precedes A\u03b240 in down Syndrome",
            "volume": "37"
        },
        "bb9500": null
    },
    "body_text": [
        {
            "endOffset": 55490,
            "parents": [],
            "secId": "s0100",
            "sentence": "We report the first application of SILK\u2122-A\u03b2 methodology to assess potential effects associated with inhibition of a CNS A\u03b2 clearance pathway following oral administration of a neprilysin inhibitor.",
            "startOffset": 55293,
            "title": "Discussion"
        },
        {
            "endOffset": 58176,
            "parents": [],
            "secId": "s0100",
            "sentence": "The elimination half-life of A\u03b2 isoforms was significantly slowed on day 1, but not altered on day 15.",
            "startOffset": 58074,
            "title": "Discussion"
        },
        {
            "endOffset": 64854,
            "parents": [],
            "secId": "s0105",
            "sentence": "The CSF pooling strategy employed to provide sufficient sample volume for assaying both A\u03b2 concentration and drug concentration was also not equivalent for pharmacokinetic and A\u03b2 assessments and so pharmacokinetic/pharmacodynamic comparisons between animals could not be conducted.",
            "startOffset": 64573,
            "title": "Study limitations"
        },
        {
            "endOffset": 30634,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Recombinant human NEP enzyme was expressed in insect cells and purified to a final concentration of 5 pM.",
            "startOffset": 30529,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 58073,
            "parents": [],
            "secId": "s0100",
            "sentence": "One possible explanation for this disparity may include that A\u03b2 pools in the brain and CSF are differentially affected by NEP inhibition.",
            "startOffset": 57936,
            "title": "Discussion"
        },
        {
            "endOffset": 61489,
            "parents": [],
            "refoffsets": {
                "bb0070": {
                    "endOffset": 61487,
                    "startOffset": 61458
                }
            },
            "secId": "s0100",
            "sentence": "Choroid plexus dysfunction has been associated with impaired A\u03b2 clearance (Gonzalez-Marrero et al., 2015).",
            "startOffset": 61383,
            "title": "Discussion"
        },
        {
            "endOffset": 41282,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "In addition, final plasma, CSF, and brain tissue samples were obtained at the scheduled necropsy on day 16 at approximately 2 hour post dose.",
            "startOffset": 41141,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 51277,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0120": {
                    "endOffset": 51275,
                    "startOffset": 51251
                }
            },
            "secId": "s0090",
            "sentence": "The 300 mg/kg dose resulted in a mean AUC(0\u201324 h) sacubitrilat exposure of 614,000 ng \u2217 h/mL and mean Cmax exposure of 143,500 ng/mL, which is approximately 4-fold (AUC(0,\u03c4)) and 10-fold (Cmax)the exposure associated with the 400 mg QD dose used in the healthy volunteer study (Langenickel et al., 2016).",
            "startOffset": 50973,
            "title": "39-week study in cynomolgus monkeys with brain A\u03b2-immunostaining"
        },
        {
            "endOffset": 43970,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Animals were randomly assigned to either vehicle control or sacubitril/valsartan treatment groups to control bias.",
            "startOffset": 43856,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 56081,
            "parents": [],
            "secId": "s0100",
            "sentence": "Although CSF concentrations of A\u03b21-42, as well as the shorter isoforms A\u03b21-40, A\u03b21-38 and total A\u03b2 were still increased at day 15, no elevations in brain A\u03b21-40, A\u03b21-42 or A\u03b21-38 were detected 2 hour post dose on day 16 and no brain amyloid deposition was detected in the 39-week study.",
            "startOffset": 55795,
            "title": "Discussion"
        },
        {
            "endOffset": 30072,
            "parents": [],
            "secId": "s0005",
            "sentence": "Localization of NEP in the cynomolgus monkey brain was also assessed by immunostaining using samples from untreated animals.",
            "startOffset": 29948,
            "title": "Introduction"
        },
        {
            "endOffset": 32934,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The IC50 values, corresponding to the inhibitor concentration showing 50% reduction of the FLT values measured in absence of an inhibitor, were calculated from the plot of percentage of inhibition vs. inhibitor concentration using non-linear regression analysis software.",
            "startOffset": 32663,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 42826,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Samples were centrifuged and analyzed by LC-MS/MS using electrospray ionization.",
            "startOffset": 42746,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 50208,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Brain levels of A\u03b21-42 or A\u03b21-40 (cerebral cortical or hippocampal) in sacubitril/valsartan-treated animals were not changed relative to controls at 2 hour post dose on day 16 (Fig. 6B).",
            "startOffset": 50022,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 64572,
            "parents": [],
            "secId": "s0105",
            "sentence": "As a result, only the stable label clearance phase was impacted by NEP inhibition on day 1 whereas both the synthesis phase and clearance phases were impacted by NEP inhibition on day 15.",
            "startOffset": 64385,
            "title": "Study limitations"
        },
        {
            "endOffset": 50972,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "There were no sacubitril/valsartan-related microscopic brain changes, increases in brain or cerebral vascular A\u03b2 content, or plaque formation after 39 weeks of dosing as assessed by H/E and A\u03b2 immunostaining.",
            "startOffset": 50764,
            "title": "39-week study in cynomolgus monkeys with brain A\u03b2-immunostaining"
        },
        {
            "endOffset": 29327,
            "parents": [],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 29325,
                    "startOffset": 29308
                }
            },
            "secId": "s0005",
            "sentence": "The SILK\u2122-A\u03b2 methodology has been previously used in monkeys to assess changes in CSF A\u03b2 associated pathways of A\u03b2 production by \u03b3-secretase inhibition (Cook et al., 2010).",
            "startOffset": 29155,
            "title": "Introduction"
        },
        {
            "endOffset": 35751,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 35749,
                    "startOffset": 35732
                }
            },
            "secId": "s0035",
            "sentence": "Surgically implanted cisterna magna catheter and port systems were employed for the serial collection of uncontaminated CSF samples as previously described (Cook et al., 2010).",
            "startOffset": 35575,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 28957,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here, we report two separate studies carried out in this model investigating effects of sacubitril/valsartan on CSF A\u03b2 clearance, A\u03b2 concentrations in CSF, brain and plasma as well as A\u03b2 brain deposition.",
            "startOffset": 28753,
            "title": "Introduction"
        },
        {
            "endOffset": 36121,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "All animals were continuously infused with 0.9% sodium chloride injection, USP, at a rate of 2.0 mL/h until initiation of treatment and in between SILK\u2122 infusions.",
            "startOffset": 35958,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 39334,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0050",
            "sentence": "The TTR and concentration of A\u03b2 was measured using a combination of immunoprecipitation and mass spectrometry (IP/MS).",
            "startOffset": 39216,
            "title": "A\u03b2 immunoassay and immunoprecipitation/liquid chromatography-mass spectrometry"
        },
        {
            "endOffset": 56615,
            "parents": [],
            "secId": "s0100",
            "sentence": "Thus, the interpretation of changes in CSF A\u03b2 associated with pharmacologic inhibition of clearance of A\u03b2 in the CNS by neprilysin could be more precisely defined.",
            "startOffset": 56452,
            "title": "Discussion"
        },
        {
            "endOffset": 58577,
            "parents": [],
            "secId": "s0100",
            "sentence": "Upregulation of A\u03b2 clearance from the brain tissue by alternative pathways, or maintained clearance of A\u03b2 through the CSF by active or passive transport, are possibilities following longer-term exposure.",
            "startOffset": 58374,
            "title": "Discussion"
        },
        {
            "endOffset": 32382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The effect of each compound on the enzymatic activity was determined after 60 min incubation at room temperature.",
            "startOffset": 32269,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 46200,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0160": {
                    "endOffset": 46145,
                    "startOffset": 46127
                }
            },
            "secId": "s0070",
            "sentence": "FFPE tissues were prepared as previously described (Pardo et al., 2012) and transverse brain sections cut for IHC assessment.",
            "startOffset": 46075,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 58373,
            "parents": [],
            "secId": "s0100",
            "sentence": "Normalization of the elimination half-life by day 15 is expected and reflects A\u03b2 clearance reaching a steady-state in the CSF with a larger pool size, thus not affecting a relative clearance rate.",
            "startOffset": 58177,
            "title": "Discussion"
        },
        {
            "endOffset": 36563,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0040",
            "sentence": "Intravenous infusion of 13C6-leucine was started at 8 pm and continued for 12 h. For A\u03b2 analysis, CSF was collected at 4, 12, 16, 20, 24, 28, 32 and 36 h after the start of 13C6-leucine infusion.",
            "startOffset": 36368,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 40977,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Blood was processed for plasma using K2EDTA (anticoagulant).",
            "startOffset": 40917,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 57822,
            "parents": [],
            "refoffsets": {
                "bb0175": {
                    "endOffset": 57820,
                    "startOffset": 57800
                }
            },
            "secId": "s0100",
            "sentence": "The relationship between CSF and brain levels of A\u03b2 is currently not well understood but a recent study in humans determined that direct transport of A\u03b2 across the blood-brain barrier may account for 25\u201350% of A\u03b2 clearance (Roberts et al., 2014).",
            "startOffset": 57576,
            "title": "Discussion"
        },
        {
            "endOffset": 27895,
            "parents": [],
            "refoffsets": {
                "bb0110": {
                    "endOffset": 27893,
                    "startOffset": 27874
                }
            },
            "secId": "s0005",
            "sentence": "The amyloid cascade hypothesis posits that abnormal production and clearance of A\u03b2 contributes to the formation of amyloid plaques, commonly found in the brains of patients with dementia due to Alzheimer's disease (AD) (Karran et al., 2011).",
            "startOffset": 27654,
            "title": "Introduction"
        },
        {
            "endOffset": 32662,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "FLT measurements were conducted on an Ultra Evolution fluorescence lifetime reader (TECAN, Maennedorf, Switzerland) with an excitation light source of 405 nm wavelength and an emission wavelength of 450 nm through a bandpass filter and analyzed using instrument control software.",
            "startOffset": 32383,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 38930,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "SILK\u2122-A\u03b2 samples were labeled as belonging to animals from one of two cohorts.",
            "startOffset": 38852,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 46451,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "These sections contained portions of the forebrain, multiple portions of the cerebrum, caudate putamen area, thalamus (rostral and caudal), and midbrain including the substantia nigra, pons, cerebellum, and multiple portions of the medulla oblongata.",
            "startOffset": 46201,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 44335,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Monkeys were of Chinese origin and aged between 2 and 4 years at the start of dosing.",
            "startOffset": 44250,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 60564,
            "parents": [],
            "secId": "s0100",
            "sentence": "The brain regions with the highest NEP expression included the basal ganglia (caudate nucleus, putamen and globus pallidus) and some thalamic, pontine, cerebellar, and medullary nuclei.",
            "startOffset": 60379,
            "title": "Discussion"
        },
        {
            "endOffset": 38851,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "This pooling strategy was selected based on modeling indicating this approach would provide the most accurate measure of the mean and result in an overestimate rather than underestimate of the actual standard deviation, relative to non-pooled samples.",
            "startOffset": 38600,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 53975,
            "parents": [],
            "secId": "s0100",
            "sentence": "In vitro testing revealed that sacubitril and its active metabolite sacubitrilat are selective for human NEP and did not inhibit other metalloproteases known to degrade A\u03b2, such as ACE-1.",
            "startOffset": 53788,
            "title": "Discussion"
        },
        {
            "endOffset": 41730,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Parameters were estimated using sampling times relative to the start of each dose administration.",
            "startOffset": 41633,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 52005,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "There was moderate NEP expression in some thalamic, pontine, cerebellar, and medullary nuclei.",
            "startOffset": 51911,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 43509,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "A retrospective analysis of A\u03b2 brain immunostaining was performed on brains from a 39-week toxicity study conducted at the facility of Charles River Laboratories, Inc., Reno, NV.",
            "startOffset": 43331,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 62039,
            "parents": [],
            "refoffsets": {
                "bb0125": {
                    "endOffset": 62037,
                    "startOffset": 61946
                },
                "bb0180": {
                    "endOffset": 62037,
                    "startOffset": 61946
                },
                "bb0195": {
                    "endOffset": 62037,
                    "startOffset": 61946
                },
                "bb0205": {
                    "endOffset": 62037,
                    "startOffset": 61946
                }
            },
            "secId": "s0100",
            "sentence": "In addition to redundant proteolytic clearance pathways, A\u03b2 is also cleared from the CNS by non-enzymatic processes, including cell mediated clearance and passive and active transport (Wang et al., 2006; Leissring, 2008; Saido and Leissring, 2012; Tarasoff-Conway et al., 2015).",
            "startOffset": 61761,
            "title": "Discussion"
        },
        {
            "endOffset": 30236,
            "parents": [],
            "secId": "s0005",
            "sentence": "Finally, a separate set of experiments was performed to determine the in vitro potency and protease selectivity profile of sacubitril, sacubitrilat, and valsartan.",
            "startOffset": 30073,
            "title": "Introduction"
        },
        {
            "endOffset": 39133,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "Analysts at C2N Diagnostics were unaware of the treatment status of the two cohorts, and analysis of samples at C2N Diagnostics was performed blinded to the treatment group of the pooled animal samples.",
            "startOffset": 38931,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 47797,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Sacubitril, sacubitrilat, and valsartan at physiologically relevant concentrations did not inhibit other metalloproteases that degrade A\u03b2 in vitro, including ACE-1 (Table 1).",
            "startOffset": 47623,
            "title": "In vitro potency and protease selectivity profile of sacubitril, sacubitrilat, and valsartan"
        },
        {
            "endOffset": 28392,
            "parents": [],
            "secId": "s0005",
            "sentence": "This study is the first reported use of SILK\u2122-A\u03b2 technology to assess changes in CSF A\u03b2 associated with inhibition of A\u03b2 clearance pathways by a neprilysin inhibitor.",
            "startOffset": 28226,
            "title": "Introduction"
        },
        {
            "endOffset": 45951,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "For NEP staining, brain sections from three na\u00efve cynomolgus monkeys (two females and one male) of Chinese origin which were 4, 5, and 23 years old were utilized.",
            "startOffset": 45789,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 32103,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "For NEP, NEP-2, ECE-1, ECE-2, and ACE-1, the enzymatic reaction was started by the addition of a synthetic peptide substrate Cys(PT14)-Arg-Arg-Leu-Trp-OH (Product number BS-# 9288.1, Biosyntan, Berlin, Germany) to produce a final concentration of 0.7 \u03bcM (0.8 \u03bcM for ACE-1).",
            "startOffset": 31830,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 64170,
            "parents": [],
            "secId": "s0105",
            "sentence": "Although A\u03b2 deposition was evaluated in animals chronically treated for 39 weeks (i.e. the maximum nonclinical study duration required by ICH guidance (ICH M3(R2) to support human clinical trials and marketing authorization) at dose levels providing sacubitrilat exposure that exceeded clinical exposures, it is acknowledged that this period of time may still not be sufficient to detect the full effects of long-term chronic treatment with sacubitril/valsartan on plaque deposition.",
            "startOffset": 63687,
            "title": "Study limitations"
        },
        {
            "endOffset": 35574,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "Female monkeys were selected based on availability and general compliance with the surgical methodology.",
            "startOffset": 35470,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 46700,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Briefly, sections were cut at 5 \u03bcm and analyzed by the Ventana Systems Discovery XT (Ventana Medical Systems Inc., Tucson, AZ).",
            "startOffset": 46573,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 66071,
            "parents": [],
            "secId": "s0125",
            "sentence": "The study was sponsored by Novartis Pharmaceuticals Corporation.",
            "startOffset": 66007,
            "title": "Funding"
        },
        {
            "endOffset": 31830,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Recombinant human angiotensin-converting enzyme-1 (ACE-1, expressed in insect cells and purified at a final concentration of 3.0 pM) was pre-incubated with sacubitril, sacubitrilat or valsartan at various concentrations for 60 min at room temperature in 10 mM sodium phosphate buffer, pH 7.4 containing 150 mM NaCl and 0.05% (w/v) CHAPS.",
            "startOffset": 31493,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 40916,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Blood and CSF samples were collected at 0.5, 1, 4, 8, and 24 hour post dose on days 1 and 15 for analysis of sacubitril, sacubitrilat, and valsartan.",
            "startOffset": 40767,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 27008,
            "parents": [],
            "refoffsets": {
                "bb0095": {
                    "endOffset": 27006,
                    "startOffset": 26946
                },
                "bb0100": {
                    "endOffset": 27006,
                    "startOffset": 26946
                },
                "bb0185": {
                    "endOffset": 27006,
                    "startOffset": 26946
                }
            },
            "secId": "s0005",
            "sentence": "The role of NEP in A\u03b2 degradation is based on both in vitro and in vivo studies (Howell et al., 1995; Takaki et al., 2000; Iwata et al., 2000).",
            "startOffset": 26865,
            "title": "Introduction"
        },
        {
            "endOffset": 40193,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0055",
            "sentence": "A two-tailed Student's t-test was used for comparisons between treatment groups.",
            "startOffset": 40113,
            "title": "Calculation of elimination half-life and newly generated A\u03b2"
        },
        {
            "endOffset": 59111,
            "parents": [],
            "secId": "s0100",
            "sentence": "This may reflect species-specific differences in the clearance of A\u03b2 or assay-specific differences in the methods used (multiplexed immunoassay vs. SILK\u2122 method, respectively).",
            "startOffset": 58935,
            "title": "Discussion"
        },
        {
            "endOffset": 65274,
            "parents": [],
            "secId": "s0110",
            "sentence": "A\u03b2 levels in the hippocampus and cerebral cortex of sacubitril/valsartan-treated animals were similar to controls 2 hour post dose on day 16 and concentrations of sacubitrilat in the brain were low.",
            "startOffset": 65076,
            "title": "Conclusion"
        },
        {
            "endOffset": 40048,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "refoffsets": {
                "bb0010": {
                    "endOffset": 40046,
                    "startOffset": 40026
                }
            },
            "secId": "s0055",
            "sentence": "Newly generated A\u03b2 was calculated as previously described as the product of the percentage of labeled A\u03b2 (LC-MS results) and the A\u03b2total concentration (LC-MS results) (Bateman et al., 2009).",
            "startOffset": 39858,
            "title": "Calculation of elimination half-life and newly generated A\u03b2"
        },
        {
            "endOffset": 61760,
            "parents": [],
            "refoffsets": {
                "bb0020": {
                    "endOffset": 61649,
                    "startOffset": 61626
                },
                "bb0155": {
                    "endOffset": 61758,
                    "startOffset": 61736
                }
            },
            "secId": "s0100",
            "sentence": "The relative contribution of different proteases, including NEP, to A\u03b2 metabolism in different species has not been entirely elucidated (Carson and Turner, 2002); nevertheless, NEP appears to play a role in A\u03b2 degradation in rodents and primates (Nalivaeva et al., 2014).",
            "startOffset": 61489,
            "title": "Discussion"
        },
        {
            "endOffset": 45068,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Multiple brain regions, including the cerebral cortex, striatum, thalamus/hypothalamus, ventricular system, limbic system (including hippocampus), midbrain, cerebellum, pons region and medulla oblongata from animals receiving control and high-dose sacubitril/valsartan (39-week study) were evaluated by immunohistochemistry (IHC).",
            "startOffset": 44738,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 56451,
            "parents": [],
            "refoffsets": {
                "bb0035": {
                    "endOffset": 56449,
                    "startOffset": 56428
                }
            },
            "secId": "s0100",
            "sentence": "Perhaps of greater importance, younger animals were selected to reduce confounding effects of a decrease in CSF A\u03b2 that accompanies age and hippocampal atrophy (Darusman et al., 2014).",
            "startOffset": 56267,
            "title": "Discussion"
        },
        {
            "endOffset": 41140,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "CSF samples were pooled from the groups of three animals within each group (three aliquots of equal volume) and diluted 1:1 with blank (i.e. naive monkey) plasma.",
            "startOffset": 40978,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 53313,
            "parents": [],
            "refoffsets": {
                "bb0110": {
                    "endOffset": 53311,
                    "startOffset": 53292
                }
            },
            "secId": "s0100",
            "sentence": "However, the role of A\u03b2 clearance in the pathophysiology of AD is not well defined, with genes associated with the disease primarily involved in the production of the A\u03b2 protein (Karran et al., 2011).",
            "startOffset": 53113,
            "title": "Discussion"
        },
        {
            "endOffset": 38069,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "Plasma samples were analyzed for labeled and unlabeled free leucine as a measure and quality control for the leucine infusion.",
            "startOffset": 37943,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 62377,
            "parents": [],
            "refoffsets": {
                "bb0115": {
                    "endOffset": 62375,
                    "startOffset": 62355
                }
            },
            "secId": "s0100",
            "sentence": "In a meta-analysis of genome wide association studies totaling 74,064 individuals, neither NEP nor other enzymes implicated in A\u03b2 enzymatic clearance were associated with late-onset AD (Lambert et al., 2013).",
            "startOffset": 62169,
            "title": "Discussion"
        },
        {
            "endOffset": 42418,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "CSF samples were processed similarly as the plasma and measured against 1:1 CSF:plasma calibration standards.",
            "startOffset": 42309,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 49917,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Plasma levels of A\u03b21-40 and A\u03b21-42 showed trends (by multiplex immunoassay) for increases in sacubitril/valsartan-treated animals at both 2 and 12 hour post-dose on days 1 and 15, with maximum increases observed at 12 hour post dose on day 15 (48.8% increase for A\u03b21-42 and 38.7% increase for A\u03b21-40, relative to concurrent controls) (Fig. 6A).",
            "startOffset": 49573,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 25576,
            "parents": [],
            "refoffsets": {
                "bb0055": {
                    "endOffset": 25574,
                    "startOffset": 25536
                },
                "bb0080": {
                    "endOffset": 25574,
                    "startOffset": 25536
                }
            },
            "secId": "s0005",
            "sentence": "Following oral administration, sacubitril/valsartan delivers systemic exposure to valsartan, an angiotensin receptor blocker (ARB) and sacubitril (also known as AHU377), an inactive prodrug which is subsequently metabolized by esterases to the active neprilysin (NEP) inhibitor sacubitrilat (also known as LBQ657) (Gu et al., 2010; Flarakos et al., 2016).",
            "startOffset": 25221,
            "title": "Introduction"
        },
        {
            "endOffset": 36966,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0040",
            "sentence": "Free leucine analysis in plasma samples (collected pre-infusion (0 min), as well as 6 min and 2, 4, 8, 12, 14 and 24 h after infusion) was conducted by Metabolic Solutions Inc. (Nashua, NH) using a validated gas chromatography/mass spectrometry (GC/MS) protocol.",
            "startOffset": 36704,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 54189,
            "parents": [],
            "secId": "s0100",
            "sentence": "Preclinical studies focused on the short-term effects of sacubitril/valsartan administration on the clearance of A\u03b2 from the CSF of cynomolgus monkeys, as well as concentrations of A\u03b2 in the CSF, brain and plasma.",
            "startOffset": 53976,
            "title": "Discussion"
        },
        {
            "endOffset": 35957,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "These monkeys were also implanted with a standard femoral vein silicone-based catheter system with the tip of the catheter approximately at the level of the vena cava for vascular infusion of 13C6-leucine.",
            "startOffset": 35752,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 40741,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0055",
            "sentence": "For A\u03b21-40, A\u03b21-38, and A\u03b2total we included hours 16-32 for the log transformation, but for A\u03b21-42 the log transformation including the 32 hour time point was not possible since the concentrations measured at this time point were too close to the lower limit of quantitation (LLOQ).",
            "startOffset": 40459,
            "title": "Calculation of elimination half-life and newly generated A\u03b2"
        },
        {
            "endOffset": 28226,
            "parents": [],
            "refoffsets": {
                "bb7000": {
                    "endOffset": 28224,
                    "startOffset": 28201
                }
            },
            "secId": "s0005",
            "sentence": "However the exact role of A\u03b2 in the subsequent pathophysiology of AD is still the subject of some debate (Sorrentino et al., 2014).",
            "startOffset": 28095,
            "title": "Introduction"
        },
        {
            "endOffset": 49068,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Stable isotope kinetic assessments showed that the elimination half-life of newly synthesized A\u03b2 was significantly increased in the 50 mg/kg sacubitril/valsartan dosing group relative to controls on day 1 for A\u03b21-42 (65.3%; p = 0.026), A\u03b21-40 (35.2%; p = 0.04) and A\u03b2total (29.8%; p = 0.04), but normalized by day 15 (Fig. 3).",
            "startOffset": 48742,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 56266,
            "parents": [],
            "secId": "s0100",
            "sentence": "Young cynomolgus monkeys were utilized in this study rather than older monkeys due to the need to collect serial CSF samples from cisterna magna ported animals over an extended period.",
            "startOffset": 56082,
            "title": "Discussion"
        },
        {
            "endOffset": 34613,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb9500": {
                    "endOffset": 34611,
                    "startOffset": 34512
                }
            },
            "secId": "s0025",
            "sentence": "All primate experiments in the studies were reviewed and approved by the Institutional Animal Care and Use Committees of either Novartis, East Hanover, NJ or Charles River Laboratories, Inc. (Reno, NV or Montreal, Quebec, Canada) and conformed to the Guide for the Use and Care of Laboratory Animals (National Research Council of the National Academies, Institute for Laboratory Animal Research, 2011).",
            "startOffset": 34211,
            "title": "Animals and housing"
        },
        {
            "endOffset": 49573,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Similar trends were noted for total (labeled + unlabeled) CSF A\u03b2 on day 15 (Fig. S1).",
            "startOffset": 49488,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 55072,
            "parents": [],
            "refoffsets": {
                "bb0120": {
                    "endOffset": 55070,
                    "startOffset": 55046
                }
            },
            "secId": "s0100",
            "sentence": "Plasma exposure to sacubitrilat in these animals was similar to [approximately 0.6-fold (AUC(0\u201324 h)) and 2.4-fold (Cmax)] the steady state exposure in the healthy volunteers (Langenickel et al., 2016).",
            "startOffset": 54870,
            "title": "Discussion"
        },
        {
            "endOffset": 53112,
            "parents": [],
            "secId": "s0100",
            "sentence": "As NEP is one of several enzymes involved in the degradation of A\u03b2, there is a theoretical risk of accumulation of A\u03b2 in the brain following inhibition of the enzyme by sacubitrilat.",
            "startOffset": 52930,
            "title": "Discussion"
        },
        {
            "endOffset": 26121,
            "parents": [],
            "refoffsets": {
                "bb0075": {
                    "endOffset": 26119,
                    "startOffset": 26083
                },
                "bb0145": {
                    "endOffset": 26119,
                    "startOffset": 26083
                }
            },
            "secId": "s0005",
            "sentence": "Based on its unique mode of action, sacubitril/valsartan exhibits beneficial effects on cardiac, renal, and vascular function, which may underlie the improved mortality and morbidity observed in patients with heart failure and reduced ejection fraction in the PARADIGM-HF trial (McMurray, 2015; Gori and Senni, 2016).",
            "startOffset": 25804,
            "title": "Introduction"
        },
        {
            "endOffset": 37327,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0040",
            "sentence": "The cisterna magna ported female cynomolgus monkeys received either vehicle control or 50 mg/kg/day sacubitril/valsartan treatment by oral gavage for up to 16 days, with SILK\u2122-A\u03b2 analyses occurring on days 1 and 15 of dosing; and tissue collections for assessment of A\u03b2 concentrations in brain, CSF and plasma occurring at necropsy (2 hour post dose on day 16).",
            "startOffset": 36966,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 37657,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0040",
            "sentence": "The first dose of sacubitril/valsartan was administered 12 h after the initiation of 13C6-leucine infusion (Fig. 1).",
            "startOffset": 37541,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 35262,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "Randomization was by stratification using body weight as the parameter.",
            "startOffset": 35191,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 35075,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "Thirty-six female cynomolgus monkeys of Chinese origin, aged between 2 and 4 years, were utilized in the 2-week SILK\u2122-A\u03b2 study for evaluating the effects of sacubitril/valsartan on CNS drug exposure and levels and clearance of A\u03b2 in CSF and plasma.",
            "startOffset": 34827,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 43733,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "In this study, sacubitril/valsartan was administered to four groups (4/sex/group) of cynomolgus monkeys at daily doses of 0 (vehicle) 30, 100 and 300 mg/kg/day (dose volume of 5 mL/kg) via nasal gavage for at least 39 weeks.",
            "startOffset": 43509,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 63686,
            "parents": [],
            "refoffsets": {
                "bb0090": {
                    "endOffset": 63684,
                    "startOffset": 63666
                }
            },
            "secId": "s0105",
            "sentence": "Furthermore, spontaneous A\u03b2 plaque formation has not been observed in cynomolgus monkeys under the age of 15 years and non-human primates do not display dementia and neurodegenerative changes present in human AD which develop over decades of life (Heuer et al., 2012).",
            "startOffset": 63418,
            "title": "Study limitations"
        },
        {
            "endOffset": 30529,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0045": {
                    "endOffset": 30527,
                    "startOffset": 30507
                }
            },
            "secId": "s0015",
            "sentence": "The in vitro potency and protease activity of sacubitril/valsartan analytes were assessed using fluorescence-based lifetime (FLT) assays as previously described for kallikrein 7 (Doering et al., 2009).",
            "startOffset": 30328,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 36703,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "refoffsets": {
                "bb0010": {
                    "endOffset": 36701,
                    "startOffset": 36681
                }
            },
            "secId": "s0040",
            "sentence": "Analysis of labeled to unlabeled (12C6) leucine in proteins was measured by the tracer-to-tracee ratio (TTR) method (Bateman et al., 2009).",
            "startOffset": 36564,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 40112,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0055",
            "sentence": "All statistical calculations were performed with GraphPad 5.04.",
            "startOffset": 40049,
            "title": "Calculation of elimination half-life and newly generated A\u03b2"
        },
        {
            "endOffset": 26864,
            "parents": [],
            "refoffsets": {
                "bb0085": {
                    "endOffset": 26862,
                    "startOffset": 26844
                }
            },
            "secId": "s0005",
            "sentence": "A\u03b2 is a peptide generated in the brain through sequential cleavage of amyloid precursor protein (APP) by \u03b2- and \u03b3- secretases (Haass et al., 2012).",
            "startOffset": 26717,
            "title": "Introduction"
        },
        {
            "endOffset": 50398,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "There were no statistically significant increases in the CSF levels of A\u03b21-42 or A\u03b21-40 in samples collected at 2 hour post dose on day 16, as assessed by a multiplex immunoassay (Fig. 6C).",
            "startOffset": 50209,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 53788,
            "parents": [],
            "refoffsets": {
                "bb0165": {
                    "endOffset": 53786,
                    "startOffset": 53765
                }
            },
            "secId": "s0100",
            "sentence": "In the present studies, the non-human primate serves as an appropriate preclinical model to investigate the pharmacological effects of both short- and long-term administration of sacubitril/valsartan, attempting to replicate the human condition of A\u03b2 production and clearance (Podlisny et al., 1991).",
            "startOffset": 53488,
            "title": "Discussion"
        },
        {
            "endOffset": 55794,
            "parents": [],
            "secId": "s0100",
            "sentence": "In a 2-week study, administration of sacubitril/valsartan resulted in acute decreases in CSF clearance rates of the more aggregable peptide A\u03b21-42 as well as the shorter form A\u03b21-40 and total A\u03b2 as evidenced by an increase in the elimination half-life; however, clearance rates had normalized by day 15.",
            "startOffset": 55491,
            "title": "Discussion"
        },
        {
            "endOffset": 43855,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Additional groups of control and 300 mg/kg/day cynomolgus monkeys (2/sex) were included to serve as recovery populations.",
            "startOffset": 43734,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 25220,
            "parents": [],
            "refoffsets": {
                "bb0150": {
                    "endOffset": 25218,
                    "startOffset": 25197
                }
            },
            "secId": "s0005",
            "sentence": "Sacubitril/valsartan (previously LCZ696) is the first angiotensin receptor neprilysin inhibitor (ARNI) approved by the US FDA and European Medicines Agency shown to reduce cardiovascular mortality and heart failure hospitalizations by 20% (McMurray et al., 2014).",
            "startOffset": 24957,
            "title": "Introduction"
        },
        {
            "endOffset": 57576,
            "parents": [],
            "secId": "s0100",
            "sentence": "Although it is reassuring that there was no evidence of A\u03b2 plaque formation by immunohistochemistry after 39-weeks of treatment with sacubitril/valsartan, it is acknowledged that we cannot rule out the potential for A\u03b2 deposition and plaque formation following longer term treatment.",
            "startOffset": 57293,
            "title": "Discussion"
        },
        {
            "endOffset": 57292,
            "parents": [],
            "secId": "s0100",
            "sentence": "These data are consistent with the absence of elevation in brain concentrations of A\u03b21-40 and A\u03b21-42 in the 2-week SILK\u2122-A\u03b2 study.",
            "startOffset": 57162,
            "title": "Discussion"
        },
        {
            "endOffset": 35470,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "In-life technicians were not blinded to treatment group assignment; however, apart from assignment to vehicle control or sacubitril/valsartan treatment groups, all animals were treated as equally as possible.",
            "startOffset": 35262,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 28752,
            "parents": [],
            "refoffsets": {
                "bb0165": {
                    "endOffset": 28750,
                    "startOffset": 28729
                }
            },
            "secId": "s0005",
            "sentence": "The cynomolgus monkey was selected as an appropriate preclinical model to assess the risk for changes in A\u03b2 clearance and brain deposition based on 1) the complete homology of APP in cynomolgus monkeys and humans, and 2) shared similarity in progressive cerebral deposition of A\u03b2 protein during normal aging not found in other species (Podlisny et al., 1991).",
            "startOffset": 28393,
            "title": "Introduction"
        },
        {
            "endOffset": 52703,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "refoffsets": {
                "bb0135": {
                    "endOffset": 52701,
                    "startOffset": 52682
                }
            },
            "secId": "s0095",
            "sentence": "The lack of NEP expression in the choroid plexus of cynomolgus monkeys contradicts published reports on human brain samples, wherein the human choroid plexus was shown to contain NEP, albeit using different methodology with potentially different sensitivities (e.g., immunoradiometric vs. IHC; specificity of antibodies - polyclonal vs. monoclonal antibodies) (Matsas et al., 1985).",
            "startOffset": 52321,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 33989,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The IC50 values, corresponding to the inhibitor concentration showing 50% reduction of the fluorescence intensity values measured in the absence of an inhibitor, were calculated as described above.",
            "startOffset": 33792,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 32268,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "refoffsets": {
                "bb0045": {
                    "endOffset": 32266,
                    "startOffset": 32246
                }
            },
            "secId": "s0015",
            "sentence": "Substrate hydrolysis led to an increase in the fluorescence lifetime (FLT) of PT14 measured by means of a FLT reader as previously described (Doering et al., 2009).",
            "startOffset": 32104,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 38368,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "Therefore, pooling of samples was necessary in order to provide sufficient sample volume for the assay.",
            "startOffset": 38265,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 47981,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Daily oral administration of sacubitril/valsartan to female cynomolgus monkeys for 16 consecutive days at 50 mg/kg/day was well tolerated.",
            "startOffset": 47843,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 65842,
            "parents": [],
            "secId": "s0110",
            "sentence": "Further clinical studies assessing cognitive function in patients with heart failure are ongoing.",
            "startOffset": 65745,
            "title": "Conclusion"
        },
        {
            "endOffset": 45789,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Positive and negative controls served to minimize bias potentially introduced by the study pathologist, who was not blinded to treatment group assignments.",
            "startOffset": 45634,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 61382,
            "parents": [],
            "secId": "s0100",
            "sentence": "It is of interest to note that the epithelial cells of the choroid plexus form the blood-CSF barrier and mediate both secretion of proteins and processes that clear substances from the CSF and blood.",
            "startOffset": 61183,
            "title": "Discussion"
        },
        {
            "endOffset": 34189,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Sacubitril/valsartan was administered in 0.5% (w/v) sodium carboxymethylcellulose, aqueous solution by either oral (2-week SILK\u2122-A\u03b2 study) or nasal gavage (39-week study).",
            "startOffset": 34018,
            "title": "Study drug and formulation"
        },
        {
            "endOffset": 33676,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Substrate hydrolysis led to an increase in fluorescence intensity measured by a monochromator-based fluorescence-reader at wavelengths of 320 nm and 405 nm taken for fluorescence excitation and emission acquisition, respectively.",
            "startOffset": 33447,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 52320,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Immunolocalization of NEP in cynomolgus monkey brain was comparable with the human brain, with the exception of the choroid plexus (Table S3).",
            "startOffset": 52178,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 58934,
            "parents": [],
            "refoffsets": {
                "bb0120": {
                    "endOffset": 58775,
                    "startOffset": 58751
                }
            },
            "secId": "s0100",
            "sentence": "In contrast to a study in healthy human volunteers, where elevations of A\u03b21-38, but not A\u03b21-40 and A\u03b21-42, were observed in the CSF following sacubitril/valsartan treatment (Langenickel et al., 2016), we report elevations in the more aggregable form A\u03b21-42, in the shorter forms A\u03b21-40, A\u03b21-38, as well as A\u03b2total in the CSF of cynomolgus monkeys at day 15.",
            "startOffset": 58577,
            "title": "Discussion"
        },
        {
            "endOffset": 60729,
            "parents": [],
            "secId": "s0100",
            "sentence": "While soluble A\u03b2 levels were not assessed in these brain regions, immunostaining for A\u03b2 in the primate model showed no evidence of A\u03b2 accumulation in these regions.",
            "startOffset": 60565,
            "title": "Discussion"
        },
        {
            "endOffset": 62168,
            "parents": [],
            "secId": "s0100",
            "sentence": "There are also no human genetic data suggesting that alteration in enzymes that remove A\u03b2 are involved in the development of AD.",
            "startOffset": 62040,
            "title": "Discussion"
        },
        {
            "endOffset": 63157,
            "parents": [],
            "secId": "s0100",
            "sentence": "The theoretical mechanistic concern of NEP inhibition impacting A\u03b2 metabolism is being further characterized in ongoing and planned clinical studies.",
            "startOffset": 63008,
            "title": "Discussion"
        },
        {
            "endOffset": 42593,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Brain tissue samples were homogenized in lysing solution to yield 0.2 mg/mL tissue homogenate and processed using protein precipitation with an acetonitrile/methanol mixture.",
            "startOffset": 42419,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 26716,
            "parents": [],
            "secId": "s0005",
            "sentence": "In the brain, NEP is one of several enzymes involved in the degradation of amyloid-\u03b2 (A\u03b2).",
            "startOffset": 26626,
            "title": "Introduction"
        },
        {
            "endOffset": 42308,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Samples were centrifuged and analyzed by LC-MS/MS using electrospray ionization (plasma sacubitril: precursor m/z 412.4 and product m/z 266.3; sacubitrilat: precursor m/z 384.3 and product m/z 266.3; valsartan: precursor m/z 436.4 and product m/z 291.3) with LLOQ of 10.0 ng/mL for the analytes using 0.025 mL of plasma.",
            "startOffset": 41988,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 46970,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "IHC protocol was optimized by antigen retrieval, a primary antibody incubation with the concentrations indicated above, horseradish peroxidase (HRP) enzymatic amplification (OmniMap anti-RbHRP secondary antibodies for 4 min, and detection with Ventana Medical Systems).",
            "startOffset": 46701,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 41516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "A non-compartmental approach consistent with the oral route of administration was used for parameter estimation.",
            "startOffset": 41404,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 49487,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Elevations were also noted after repeated daily dosing (day 15) for newly synthesized shorter forms including A\u03b21-40 (23.4%; p = 0.009), A\u03b21-38 (64.1%; p = 0.0001) and for newly synthesized A\u03b2total (50.45%; p = 0.00002) (Fig. 4 and Fig. 5).",
            "startOffset": 49247,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 63007,
            "parents": [],
            "refoffsets": {
                "bb0150": {
                    "endOffset": 62847,
                    "startOffset": 62826
                }
            },
            "secId": "s0100",
            "sentence": "Treatment with ARNI, sacubitril/valsartan, resulted in an overwhelming benefit of sacubitril/valsartan on morbidity and mortality in patients with heart failure with reduced ejection fraction (McMurray et al., 2014) leading to early study termination due to efficacy and expedited review and approval by the US Food and Drug Administration and the European Medicines Agency.",
            "startOffset": 62633,
            "title": "Discussion"
        },
        {
            "endOffset": 30956,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A similar protocol was followed for recombinant human NEP-2 with a final enzyme concentration of 3 pM.",
            "startOffset": 30854,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 45390,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The results were compared with sections from an A\u03b21-42-positive human brain affected with AD, which served as a positive control.",
            "startOffset": 45261,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 46074,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "These monkeys were used as vehicle controls in other experiments and did not show any neurological signs during the study.",
            "startOffset": 45952,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 34777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The study was conducted at the facility of Charles River Laboratories, Inc., Montreal, Quebec, Canada.",
            "startOffset": 34675,
            "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
        },
        {
            "endOffset": 31184,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Recombinant human endothelin-converting enzyme-1 (ECE-1) and recombinant human endothelin-converting enzyme-2 (ECE-2) were purchased from R&D Systems (Minneapolis, MN) with a final concentration of 0.3 pM and 2 pM, respectively.",
            "startOffset": 30956,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 47080,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Stained slides were scanned with an Aperio slide scanner (Leica Biosystems, Vista, CA) at 20 \u00d7 magnification.",
            "startOffset": 46971,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 44042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Randomization was by stratification using body weight as the parameter.",
            "startOffset": 43971,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 51719,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "The distribution and staining intensity of NEP was similar across all three animals (age ranging from 4 to 23 years).",
            "startOffset": 51602,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 52178,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "Notably, the choroid plexus did not show NEP immunoreactivity.",
            "startOffset": 52116,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 64384,
            "parents": [],
            "secId": "s0105",
            "sentence": "In the 2-week SILK\u2122-A\u03b2 study, differences were observed in the elimination half-life between day 1 and day 15 and may be expected based on the day 1 non-steady state condition and the day 15 steady state condition.",
            "startOffset": 64170,
            "title": "Study limitations"
        },
        {
            "endOffset": 27653,
            "parents": [],
            "refoffsets": {
                "bb0180": {
                    "endOffset": 27651,
                    "startOffset": 27626
                }
            },
            "secId": "s0005",
            "sentence": "In addition to proteolytic degradation, A\u03b2 is also cleared from the central nervous system (CNS) by non-enzymatic processes, including cell-mediated clearance and passive and active transport into the cerebrospinal fluid (CSF) and blood stream however, the relative contribution of each of these clearance pathways, including proteolytic degradation by NEP, has yet to be elucidated (Saido and Leissring, 2012).",
            "startOffset": 27242,
            "title": "Introduction"
        },
        {
            "endOffset": 60378,
            "parents": [],
            "refoffsets": {
                "bb0005": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0015": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0025": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0060": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0135": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0140": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0170": {
                    "endOffset": 60181,
                    "startOffset": 60008
                },
                "bb0190": {
                    "endOffset": 60181,
                    "startOffset": 60008
                }
            },
            "secId": "s0100",
            "sentence": "Across species, there is weak to no expression of NEP in the regions associated with A\u03b2 plaque formation, namely the cerebral cortex and hippocampus (Matsas et al., 1985; Matsas et al., 1986; Pollard et al., 1987; Bourne et al., 1989; Gaudoux et al., 1993; Akiyama et al., 2001; Takeuchi et al., 2008; Chambers et al., 2010), potentially reinforcing the importance of other A\u03b2 clearance pathways in these areas; immunostaining for A\u03b2 in the cynomolgus monkey brain showed no evidence of A\u03b2 accumulation in these regions.",
            "startOffset": 59858,
            "title": "Discussion"
        },
        {
            "endOffset": 39794,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0050",
            "sentence": "The absolute quantitation of A\u03b2 (A\u03b21-38, A\u03b21-40 and A\u03b21-42) in plasma samples from days 1 and 15 and in brain, CSF and plasma samples from 2 hour post dose on day 16 was determined by multiplex immunoassay (MesoScale Diagnostics Rodent/Human (4G8) A\u03b2 3-plex Ultra-Sensitive Kit (MesoScale Diagnostics, Rockville, MD)).",
            "startOffset": 39476,
            "title": "A\u03b2 immunoassay and immunoprecipitation/liquid chromatography-mass spectrometry"
        },
        {
            "endOffset": 61182,
            "parents": [],
            "secId": "s0100",
            "sentence": "However, the absence of NEP expression in the primate choroid plexus would suggest that elevations of CSF A\u03b2 are not related to inhibition of NEP in the choroid plexus.",
            "startOffset": 61014,
            "title": "Discussion"
        },
        {
            "endOffset": 63417,
            "parents": [],
            "secId": "s0105",
            "sentence": "Limitations of this study included the age and health status of animals used, given that young (2\u20134-year old) healthy cynomolgus monkeys are not representative of the older heart failure population that will be prescribed sacubitril/valsartan.",
            "startOffset": 63174,
            "title": "Study limitations"
        },
        {
            "endOffset": 47622,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Sacubitrilat was selective for NEP.",
            "startOffset": 47587,
            "title": "In vitro potency and protease selectivity profile of sacubitril, sacubitrilat, and valsartan"
        },
        {
            "endOffset": 43224,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "The ionization outputs for CSF and brain homogenates were precursor m/z 412.3 and product m/z 266.2 for sacubitril, precursor m/z 384.3 and product m/z 266.2 for sacubitrilat, and precursor m/z 436.4 and product m/z 235.1 for valsartan with LLOQ of 0.1 ng/mL using 0.025 mL of CSF:plasma and 0.5 ng/mL using 0.030 mL of brain tissue homogenate, respectively, for the sacubitril/valsartan analytes.",
            "startOffset": 42827,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 65493,
            "parents": [],
            "secId": "s0110",
            "sentence": "The relationship between A\u03b2 concentrations in the CSF and brain are not well understood.",
            "startOffset": 65405,
            "title": "Conclusion"
        },
        {
            "endOffset": 29947,
            "parents": [],
            "refoffsets": {
                "bb0050": {
                    "endOffset": 29824,
                    "startOffset": 29793
                }
            },
            "secId": "s0005",
            "sentence": "The second study in cynomolgus monkeys treated for 39 weeks with sacubitril/valsartan assessed brain A\u03b2 plaque formation by immunohistochemistry; this study is the longest duration nonclinical safety study in non-rodents required by ICH guidance (ICH M3 R2) (2009) to support human clinical trials marketing authorization among the regions of European Union, Japan and the United States.",
            "startOffset": 29560,
            "title": "Introduction"
        },
        {
            "endOffset": 40458,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0055",
            "sentence": "Elimination half-life was calculated using the following formula: eT\u00bd = ln(2) / k, where the elimination constant (k) is equal to the negative slope of the natural log transformed newly generated A\u03b2 concentration during the clearance portion of the metabolic study.",
            "startOffset": 40193,
            "title": "Calculation of elimination half-life and newly generated A\u03b2"
        },
        {
            "endOffset": 44466,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Animals were euthanized at the end of the 39-week dosing period (24 h after final dose) or at the end of a 4-week recovery period.",
            "startOffset": 44336,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 62633,
            "parents": [],
            "refoffsets": {
                "bb0040": {
                    "endOffset": 62631,
                    "startOffset": 62612
                }
            },
            "secId": "s0100",
            "sentence": "Furthermore, persons with a complete loss of NEP protein have not been reported to display overt early onset impairment of cognitive function, although no brain imaging studies or specific cognitive tests were reportedly carried out (Debiec et al., 2004).",
            "startOffset": 62378,
            "title": "Discussion"
        },
        {
            "endOffset": 50764,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "Brain immunostaining for A\u03b2 using an antibody which recognizes multiple isoforms of the protein (including A\u03b21-37, A\u03b21-38, A\u03b21-40, and A\u03b21-42) showed no evidence of sacubitril/valsartan-related increases in A\u03b2 deposition or A\u03b2 plaque formation following 39 weeks of dosing at 300 mg/kg/day (Fig. 7).",
            "startOffset": 50465,
            "title": "39-week study in cynomolgus monkeys with brain A\u03b2-immunostaining"
        },
        {
            "endOffset": 53487,
            "parents": [],
            "secId": "s0100",
            "sentence": "Clinical data from the landmark PARADIGM-HF trial found no signal for cognitive impairment in over 4100 patients treated with sacubitril/valsartan for a median of 27 months.",
            "startOffset": 53314,
            "title": "Discussion"
        },
        {
            "endOffset": 44250,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "In-life technicians were not blinded to treatment group assignment; however apart from assignment to vehicle control or sacubitril/valsartan treatment groups, all animals were treated as equally as possible.",
            "startOffset": 44043,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 65075,
            "parents": [],
            "secId": "s0110",
            "sentence": "In conclusion, these data show sacubitril/valsartan acutely impaired the clearance of A\u03b2 isoforms from the CNS of cynomolgus monkeys, but clearance normalized by day 15 as expected due to steady state kinetics.",
            "startOffset": 64865,
            "title": "Conclusion"
        },
        {
            "endOffset": 36367,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 36365,
                    "startOffset": 36348
                }
            },
            "secId": "s0040",
            "sentence": "In preparation for each 13C6-leucine infusion and SILK\u2122-A\u03b2 sampling, cynomolgus monkeys were restricted to a low leucine diet of vegetables and fruits as previously described (Cook et al., 2010).",
            "startOffset": 36172,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 44715,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0065",
            "sentence": "Histopathology assessments were performed on routine formalin-fixed paraffin-embedded (FFPE) brain sections from all animals, and immunohistochemical analyses for A\u03b2 were performed on control and 300 mg/kg/day main study and recovery phase animals.",
            "startOffset": 44467,
            "title": "39-week repeated dose study with sacubitril/valsartan in cynomolgus monkeys: brain immunostaining for A\u03b2"
        },
        {
            "endOffset": 31493,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "ECE-1 and ECE-2 were pre-incubated with sacubitril, sacubitrilat or valsartan at various concentrations for 60 min at room temperature in 50 mM Tris-HCl buffer, pH 7.4 containing 150 mM NaCl and 0.05% (w/v) CHAPS, and 50 mM MES-HCl buffer, pH 5.75, containing 125 mM NaCl and 0.05% (w/v) CHAPS, respectively.",
            "startOffset": 31185,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 54869,
            "parents": [],
            "refoffsets": {
                "bb0120": {
                    "endOffset": 54867,
                    "startOffset": 54843
                }
            },
            "secId": "s0100",
            "sentence": "The Cmax of sacubitrilat CSF exposure (19.8 ng/mL) on day 15 in cynomolgus monkeys was approximately equal to the Cmax CSF exposure (19.2 ng/mL) in sacubitril/valsartan-treated healthy volunteers administered 400 mg sacubitril/valsartan QD (Langenickel et al., 2016).",
            "startOffset": 54602,
            "title": "Discussion"
        },
        {
            "endOffset": 47301,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The NEP immunohistochemical analysis was scored by a pathologist (C. S.) on a semi-quantitative scale (0 to 4 +, where 0 indicates no evidence of staining) by measuring the intensity and distribution of specific staining.",
            "startOffset": 47080,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 47586,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0080",
            "sentence": "Following administration, sacubitril/valsartan dissociates into the inactive prodrug sacubitril, which is further metabolized to active NEP inhibitor sacubitrilat, and ARB valsartan.",
            "startOffset": 47404,
            "title": "In vitro potency and protease selectivity profile of sacubitril, sacubitrilat, and valsartan"
        },
        {
            "endOffset": 60929,
            "parents": [],
            "refoffsets": {
                "bb0135": {
                    "endOffset": 60927,
                    "startOffset": 60908
                }
            },
            "secId": "s0100",
            "sentence": "Our studies demonstrate that NEP was not expressed in the choroid plexus of cynomolgus monkeys; this is in contrast to demonstrated expression of NEP in the human choroid plexus (Matsas et al., 1985).",
            "startOffset": 60729,
            "title": "Discussion"
        },
        {
            "endOffset": 65404,
            "parents": [],
            "secId": "s0110",
            "sentence": "These data potentially indicate that compensatory mechanisms may be in place to restore A\u03b2 clearance with chronic NEP inhibition.",
            "startOffset": 65275,
            "title": "Conclusion"
        },
        {
            "endOffset": 28094,
            "parents": [],
            "refoffsets": {
                "bb0065": {
                    "endOffset": 28092,
                    "startOffset": 28026
                },
                "bb0105": {
                    "endOffset": 28092,
                    "startOffset": 28026
                },
                "bb9005": {
                    "endOffset": 28092,
                    "startOffset": 28026
                }
            },
            "secId": "s0005",
            "sentence": "Aggregation prone A\u03b2 subtypes (A\u03b21-42 and A\u03b21-40) are found in senile plaques of the brains of patients with Alzheimer's disease (Glenner et al., 1984; Iwatsubo et al., 1994; Iwatsubo et al., 1995).",
            "startOffset": 27896,
            "title": "Introduction"
        },
        {
            "endOffset": 26626,
            "parents": [],
            "refoffsets": {
                "bb0130": {
                    "endOffset": 26624,
                    "startOffset": 26601
                }
            },
            "secId": "s0005",
            "sentence": "In mammals, NEP is expressed in several organs, including the kidney, lung, and brain, with the renal proximal tubule displaying the highest levels (Mangiafico et al., 2013).",
            "startOffset": 26452,
            "title": "Introduction"
        },
        {
            "endOffset": 42745,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Measurements were made against brain tissue homogenate calibration standards and the nominal concentrations were corrected by tissue mass (e.g., ng/g).",
            "startOffset": 42594,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 54321,
            "parents": [],
            "secId": "s0100",
            "sentence": "Another study evaluated the long-term effects of the drug on A\u03b2 deposition in the brain of cynomolgus monkeys treated for 39 weeks.",
            "startOffset": 54190,
            "title": "Discussion"
        },
        {
            "endOffset": 51910,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "NEP was predominantly localized in basal ganglia (caudate nucleus, putamen, and globus pallidus) with intense immunostaining within neuropil (perineuronal) and axon bundle (Fig. 8, Table S2).",
            "startOffset": 51719,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 49246,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "The concentration of newly generated A\u03b2 (AUC(0\u201324 h)) was acutely increased compared to vehicle control for A\u03b2 1-42 on day 1 (20.4%; p = 0.039) and on day 15 (34.7%; p = 0.0003).",
            "startOffset": 49068,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 38599,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "CSF samples from 3 animals were pooled in rank order based on individual leucine exposure (i.e. lowest to highest free plasma leucine levels) and analyzed for labeled and unlabeled A\u03b21-37, 1-38, 1-40, 1-42, and A\u03b2total (Table S1).",
            "startOffset": 38369,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 41403,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Toxicokinetic parameters were estimated using Watson LIMS.",
            "startOffset": 41345,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 51547,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0090",
            "sentence": "If one considers the recommended clinical dose (200 mg BID) for treating patients with heart failure, exposure is approximately 2-fold (AUC(0\u201324 h)), and 9-fold (Cmax) the exposure associated with this dose (AUC(0 \u2212 12 h) of 151,611 ng \u2217 h/mL and Cmax of 16,531 ng/mL).",
            "startOffset": 51278,
            "title": "39-week study in cynomolgus monkeys with brain A\u03b2-immunostaining"
        },
        {
            "endOffset": 52115,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0095",
            "sentence": "However, weak immunostaining was noted in hippocampus and cerebral cortex within neuropil and in glial cells.",
            "startOffset": 52006,
            "title": "Immunolocalization of NEP in cynomolgus monkey brain"
        },
        {
            "endOffset": 59513,
            "parents": [],
            "secId": "s0100",
            "sentence": "Indeed, there were no statistically significant increases in CSF levels of A\u03b21-42 or A\u03b21-40 in the samples collected at 2 hour post dose on day 16, as assessed by a multiplex immunoassay (Fig. 6C); however, large inter-animal variability in CSF levels may also have confounded the interpretation of detectable changes in these single timepoint evaluations, given the relatively small-sized sample set.",
            "startOffset": 59112,
            "title": "Discussion"
        },
        {
            "endOffset": 30853,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Sacubitril, sacubitrilat or valsartan were added at concentrations ranging from 0.0003 nM to 100 \u03bcM for 60 min at room temperature in 10 mM sodium phosphate buffer, pH 7.4, containing 150 mM NaCl and 0.05% (v/v) CHAPS.",
            "startOffset": 30635,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 45633,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "An irrelevant rabbit IgG (Cat# 3900 Cell Signaling Technology) control slide was included for each section tested.",
            "startOffset": 45519,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 55293,
            "parents": [],
            "secId": "s0100",
            "sentence": "Despite very low CSF and brain penetration of valsartan, sacubitril, and sacubitrilat (\u2264 0.0044 CSF:plasma ratio; \u2264 0.0326 brain tissue:plasma ratio), concentrations of sacubitrilat were sufficient to inhibit neprilysin.",
            "startOffset": 55073,
            "title": "Discussion"
        },
        {
            "endOffset": 50022,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Similar trends were observed for 2 hour post dose day 16 samples collected at necropsy (data not shown).",
            "startOffset": 49918,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 61013,
            "parents": [],
            "secId": "s0100",
            "sentence": "The significance of this apparent species difference with regards to A\u03b2 is unclear.",
            "startOffset": 60930,
            "title": "Discussion"
        },
        {
            "endOffset": 52929,
            "parents": [],
            "refoffsets": {
                "bb0150": {
                    "endOffset": 52927,
                    "startOffset": 52906
                }
            },
            "secId": "s0100",
            "sentence": "Sacubitril/valsartan has been shown to reduce cardiovascular mortality and morbidity by 20% in patients with reduced ejection fraction heart failure compared with the ACE inhibitor enalapril (McMurray et al., 2014).",
            "startOffset": 52714,
            "title": "Discussion"
        },
        {
            "endOffset": 57935,
            "parents": [],
            "secId": "s0100",
            "sentence": "The reasons why sacubitril/valsartan-associated A\u03b2 increases occurred in CSF but not in the brain are not clear.",
            "startOffset": 57823,
            "title": "Discussion"
        },
        {
            "endOffset": 41632,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "All parameters were generated from the concentrations in plasma and CSF from days 1 and 15 unless otherwise stated.",
            "startOffset": 41517,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 45518,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "In FFPE AD brain sections, this protocol stained both compact and diffuse plaques with minimal background of adjacent neuropil.",
            "startOffset": 45391,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 27241,
            "parents": [],
            "refoffsets": {
                "bb0180": {
                    "endOffset": 27239,
                    "startOffset": 27214
                }
            },
            "secId": "s0005",
            "sentence": "In addition to NEP, there are several other A\u03b2 degrading proteases, including NEP-2, insulin degrading enzyme (IDE), endothelin converting enzyme (ECE) and angiotensin-converting enzyme (ACE) (reviewed by Saido and Leissring, 2012).",
            "startOffset": 27009,
            "title": "Introduction"
        },
        {
            "endOffset": 38264,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0045",
            "sentence": "Due to the smaller size of the cynomolgus monkeys on the study, and in consideration of animal welfare, it was possible to collect only 200\u2013225 \u03bcL of CSF per sampling timepoint during the study.",
            "startOffset": 38070,
            "title": "Pooling strategy for A\u03b2 analysis"
        },
        {
            "endOffset": 48356,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "All animals showed quantifiable amounts of valsartan, sacubitril, and sacubitrilat in both plasma and CSF (Fig. 2), with CSF concentrations of sacubitrilat exceeding the in vitro IC50 for human NEP inhibition (2.3 nM) (Table 2).",
            "startOffset": 48128,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 57161,
            "parents": [],
            "secId": "s0100",
            "sentence": "In the chronic study, cynomolgus monkeys were treated with high doses of sacubitril/valsartan (300 mg/kg/day) for 39 weeks that resulted in higher sacubitrilat exposure as compared to 200 mg BID clinical dose in humans (AUC(0\u201324 h) exposure approximately 2-fold and Cmax exposure approximately 9-fold); however, these animals displayed no sacubitril/valsartan-related microscopic brain changes or A\u03b2 deposition (as assessed by immunostaining using an antibody that cross-reacts with several isoforms including A\u03b21-37, A\u03b21-38, A\u03b21-40, and A\u03b21-42).",
            "startOffset": 56615,
            "title": "Discussion"
        },
        {
            "endOffset": 29154,
            "parents": [],
            "secId": "s0005",
            "sentence": "The 2-week SILK\u2122-A\u03b2 study was an investigative study to evaluate the effect of sacubitril/valsartan treatment on A\u03b2 concentrations and clearance in serial samples of CSF using the SILK\u2122 technique.",
            "startOffset": 28958,
            "title": "Introduction"
        },
        {
            "endOffset": 39475,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0050",
            "sentence": "This method allowed the detection of newly synthesized (labeled) A\u03b2 peptides as well as A\u03b2total (labeled and unlabeled) peptides (Table S1).",
            "startOffset": 39335,
            "title": "A\u03b2 immunoassay and immunoprecipitation/liquid chromatography-mass spectrometry"
        },
        {
            "endOffset": 33446,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The enzymatic reaction was started by the addition of a synthetic peptide substrate Mca Arg-Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys(Dnp)-OH (R&D Systems Europe Ltd., Abingdon, United Kingdom) to produce a final concentration of 2 \u03bcM.",
            "startOffset": 33221,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 65586,
            "parents": [],
            "secId": "s0110",
            "sentence": "Brain immunostaining of primates treated for 39 weeks revealed no evidence of A\u03b2 deposition.",
            "startOffset": 65494,
            "title": "Conclusion"
        },
        {
            "endOffset": 29559,
            "parents": [],
            "refoffsets": {
                "bb0030": {
                    "endOffset": 29557,
                    "startOffset": 29540
                }
            },
            "secId": "s0005",
            "sentence": "This technique was selected because it provides the most reliable estimate of the clearance of newly generated A\u03b2 peptides from the CSF compartment given constraints in CSF sampling volume and study sample size (Cook et al., 2010).",
            "startOffset": 29328,
            "title": "Introduction"
        },
        {
            "endOffset": 41987,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "Plasma samples were processed by liquid-liquid extraction procedure using methyl t-butyl ether, followed by recovery of the organic portion of the extracts by drying down at 40 \u00b0C under nitrogen and reconstitution in methanol:water:formic acid (90:10:0.1).",
            "startOffset": 41731,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 45260,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "The FFPE brain sections were stained with hematoxylin/eosin (H/E) and for A\u03b2 using a rabbit monoclonal antibody (D12B2, Cat#9888, Cell Signaling Technology, Danvers, MA) at a 1:1600 dilution.",
            "startOffset": 45069,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 37906,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0040",
            "sentence": "The final sample size was n = 17 for the control group and n = 15 for the sacubitril/valsartan treatment group due to the loss of port patency in individual animals and was independent of, and occurred prior to, sacubitril/valsartan administration.",
            "startOffset": 37658,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 41345,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0060",
            "sentence": "All samples were frozen at or below \u2212 60 \u00b0C prior to analysis.",
            "startOffset": 41283,
            "title": "Bioanalytical methods"
        },
        {
            "endOffset": 48128,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "No treatment-related changes were observed on clinical signs, body weight, food intake, body temperature, or macroscopic observations at necropsy.",
            "startOffset": 47982,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        },
        {
            "endOffset": 37540,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0040",
            "sentence": "The dose of 50 mg/kg/day was chosen as it results in plasma AUC(0\u201324 h) and Cmax sacubitrilat exposure similar to the clinical exposure delivered by a 400 mg QD dose of sacubitril/valsartan in healthy volunteers.",
            "startOffset": 37328,
            "title": "13C6-leucine infusion and treatment initiation"
        },
        {
            "endOffset": 59858,
            "parents": [],
            "secId": "s0100",
            "sentence": "Given that CSF concentrations of A\u03b21-40 and A\u03b21-42 were unaltered in healthy volunteers administered sacubitril/valsartan (400 mg QD for 2 weeks), this may suggest a limited contribution of NEP to the A\u03b2 degrading capacity and/or a possible up-regulation of redundant pathways for A\u03b2 clearance in humans, which may differ in non-human primates.",
            "startOffset": 59514,
            "title": "Discussion"
        },
        {
            "endOffset": 54601,
            "parents": [],
            "secId": "s0100",
            "sentence": "Administration of sacubitril/valsartan to female non-human primates at a dose of 50 mg/kg resulted in clinically relevant exposure to sacubitrilat in plasma and CSF that was similar to that observed in healthy volunteers receiving a 400 mg once daily dose of sacubitril/valsartan.",
            "startOffset": 54321,
            "title": "Discussion"
        },
        {
            "endOffset": 33220,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Recombinant human insulin-degrading enzyme (IDE, R&D Systems, final concentration 0.2 nM) was pre-incubated with sacubitril, sacubitrilat or valsartan at various concentrations for 60 min at room temperature in 50 mM Tris/HCl buffer at pH 7.4, containing 1 M NaCl and 0.05% (w/v) CHAPS.",
            "startOffset": 32934,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 26451,
            "parents": [],
            "refoffsets": {
                "bb0130": {
                    "endOffset": 26449,
                    "startOffset": 26390
                },
                "bb0145": {
                    "endOffset": 26449,
                    "startOffset": 26390
                },
                "bb0200": {
                    "endOffset": 26449,
                    "startOffset": 26390
                }
            },
            "secId": "s0005",
            "sentence": "NEP cleaves a number of physiologically relevant substrates, including NPs (atrial natriuretic peptide (ANP), C-type natriuretic peptide (CNP), and to a lesser degree B-type natriuretic peptide (BNP)), enkephalins, tachykinins, chemotactic peptide, and adrenomedullin (Mangiafico et al., 2013; McMurray, 2015; Volpe et al., 2016).",
            "startOffset": 26121,
            "title": "Introduction"
        },
        {
            "endOffset": 66000,
            "parents": [],
            "secId": "s0120",
            "sentence": "The Transparency document associated with this article can be found, in online version.",
            "startOffset": 65913,
            "title": "Transparency document"
        },
        {
            "endOffset": 33791,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The effect of the compound on the enzymatic activity was determined after a 60-min incubation at room temperature.",
            "startOffset": 33677,
            "title": "In vitro potency and protease selectivity profile of compounds used"
        },
        {
            "endOffset": 35190,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                },
                {
                    "id": "s0030",
                    "title": "2-week SILK\u2122-A\u03b2 study in cisterna magna ported monkey model"
                }
            ],
            "secId": "s0035",
            "sentence": "Animals were randomly assigned to either vehicle control or sacubitril/valsartan treatment groups to control bias.",
            "startOffset": 35076,
            "title": "Cisterna magna ported cynomolgus monkey model"
        },
        {
            "endOffset": 65744,
            "parents": [],
            "secId": "s0110",
            "sentence": "In view of the absence of A\u03b2 accumulation in the brain, the clinical relevance of acutely-impaired clearance of A\u03b2 from the CSF by NEP inhibition is unclear.",
            "startOffset": 65587,
            "title": "Conclusion"
        },
        {
            "endOffset": 25803,
            "parents": [],
            "secId": "s0005",
            "sentence": "This results in simultaneous enhancement of the effects of biologically-active beneficial natriuretic peptides (NPs) via inhibition of their degradation by NEP and blockade of the detrimental effects of angiotensin II via ARB.",
            "startOffset": 25577,
            "title": "Introduction"
        },
        {
            "endOffset": 46573,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0070",
            "sentence": "Anti-NEP (CD10) rabbit monoclonal antibody (clone SP67) (Ventana Medical Systems Inc., Tuscon, AZ) was used at 0.3 \u03bcg/mL.",
            "startOffset": 46452,
            "title": "Immunohistochemistry"
        },
        {
            "endOffset": 48742,
            "parents": [
                {
                    "id": "s0075",
                    "title": "Results"
                }
            ],
            "secId": "s0085",
            "sentence": "Concentrations of valsartan, sacubitril, and sacubitrilat observed in the CSF and brain were low (\u2264 0.0044 CSF:plasma ratio; \u2264 0.0326 brain tissue:plasma ratio) when compared to the plasma concentrations at 2 hour post dose on day 16 (Table 2), consistent with the high plasma protein binding of sacubitril (93% protein bound) and valsartan (95.8% protein bound) in non-human primates.",
            "startOffset": 48357,
            "title": "2-week SILK\u2122-A\u03b2 study in cynomolgus monkeys"
        }
    ],
    "docId": "S0041008X17301187",
    "metadata": {
        "asjc": [
            "3004",
            "3005"
        ],
        "authors": [
            {
                "email": "heidi.schoenfeld@novartis.com",
                "first": "Heidi A.",
                "initial": "H.A.",
                "last": "Schoenfeld"
            },
            {
                "email": null,
                "first": "Tim",
                "initial": "T.",
                "last": "West"
            },
            {
                "email": null,
                "first": "Philip B.",
                "initial": "P.B.",
                "last": "Verghese"
            },
            {
                "email": null,
                "first": "Mary",
                "initial": "M.",
                "last": "Holubasch"
            },
            {
                "email": null,
                "first": "Neeta",
                "initial": "N.",
                "last": "Shenoy"
            },
            {
                "email": null,
                "first": "David",
                "initial": "D.",
                "last": "Kagan"
            },
            {
                "email": null,
                "first": "Chiara",
                "initial": "C.",
                "last": "Buono"
            },
            {
                "email": null,
                "first": "Wei",
                "initial": "W.",
                "last": "Zhou"
            },
            {
                "email": null,
                "first": "Marc",
                "initial": "M.",
                "last": "DeCristofaro"
            },
            {
                "email": null,
                "first": "Julie",
                "initial": "J.",
                "last": "Douville"
            },
            {
                "email": null,
                "first": "Geoffrey G.",
                "initial": "G.G.",
                "last": "Goodrich"
            },
            {
                "email": null,
                "first": "Keith",
                "initial": "K.",
                "last": "Mansfield"
            },
            {
                "email": null,
                "first": "Chandra",
                "initial": "C.",
                "last": "Saravanan"
            },
            {
                "email": null,
                "first": "Frederic",
                "initial": "F.",
                "last": "Cumin"
            },
            {
                "email": null,
                "first": "Randy L.",
                "initial": "R.L.",
                "last": "Webb"
            },
            {
                "email": null,
                "first": "Randall J.",
                "initial": "R.J.",
                "last": "Bateman"
            }
        ],
        "doi": "10.1016/j.taap.2017.03.014",
        "firstpage": "53",
        "issn": "0041008X",
        "keywords": [
            "Alzheimer's disease",
            "Amyloid beta",
            "Angiotensin receptor neprilysin inhibitor",
            "LCZ696",
            "SILK-A\u03b2",
            "Sacubitril/valsartan"
        ],
        "lastpage": "65",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "PHAR"
        ],
        "title": "The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-\u03b2 concentrations and clearance in the cynomolgus monkey"
    }
}